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PREFACE
Polycystic ovary syndrome is a common and distressing
condition associated with infrequent or absent menstruation
and often hirsutism. The cause is unknown but it seems that
there is an imbalance between the hormones in the brain, in
particular luteinising hormone (LH), and the response of the
ovary. Some evidence suggests that there is a deficiency of
dopamine (DA) in an area of the brain called the hypothalamus
resulting indirectly in excess secretion of LH and that this
may be the fundamental problem in PCOS. This evidence is
based on two observations. Firstly that the hormone
prolactin is increased slightly in some patients with PCOS
and secondly that the dopamine agonist bromocriptine may
reduce LH concentrations and have a beneficial therapeutic
effect. The aim of this thesis was to examine this evidence
in detail. Sixty-nine patients with PCOS were involved in
the studies. Basal prolactin secretion was evaluated taking
account of its complicated physiological variations. Also
the response to several agents which stimulate prolactin
release was measured. To assess the effect of bromocriptine,
a double blind controlled trial was conducted. The possible
effect on the complex pulsatile nature of LH secretion was
investigated during this trial. The results showed that
prolactin secretion was no different from that of normal
women and that previous observations of abnormality may have
been due to a failure to take adequate account of the normal
(i)
variations of spontaneous prolactin secretion or the
preceding ovarian function. The controlled trial did not
confirm the previously reported beneficial effect of bromo¬
criptine in PCOS. In addition LH secretion was not altered
by bromocriptine. However a new approach to the analysis of
the pulsatile patterns of LH release suggests that the
frequency of pulses is increased in PCOS. Physiologically
this can only be explained by an abnormality in the hypo¬
thalamus. Therefore, although this study has not confirmed
an abnormality of dopamine in PCOS, it offers further
evidence in support of a hypothalamic problem in this
disease. Further investigation should therefore be directed
at this site.
The studies described in this thesis were conducted at
the Royal Victoria Infirmary, Newcastle upon Tyne between
1982 and 1985. I am most grateful to Professor Pat Kendall-
Taylor for her ideas and advice in the initial planning of
the work and for her continuing support during the study.
Particular thanks are also due to Professor Bill Dunlop for
his encouragement and patience, and for his invaluable advice
with the presentation of the results. The excellent
technical advice and assistance of Mrs Linda Brown with the
assays is acknowledged and the nursing skills of Sister Esme
Harris and Sister Mavis Harris and their staff were greatly
appreciated by patients and volunteers. For the statistical
(ii)
analysis of serial data by time series analysis, the expert
assistance of Dr Peter Diggle, Department of Statistics,
University of Newcastle upon Tyne, was gratefully received.
Mr Ken MacClean of the Department of Medical Photography took
the photographs in the hirsutism study and thereby assured
their high standard. Finally the co-operation of the
patients and normal volunteers who agreed to participate in
this study is acknowledged since this thesis would not have
been possible without their help.
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Physicians of the utmost fame
Were called at once, but when they came
They answered, as they took their fees
'There is no cure for this disease.*
(Belloc)
Sadly, such an answer awaits those who suffer from poly¬
cystic ovary syndrome (PCOS). Despite a century of recognition,
there is still no cure and this reflects a failure to understand
the basic pathology. Ovarian function is clearly disordered in
PCOS although the precise mechanism of this dysfunction is
unknown. Control of the ovary involves a complex and delicate
interplay between its own hormones and those of the brain and it
is this endocrine system that is abnormal in PCOS.In this study an
attempt has been made to test an hypothesis related to one
possible endocrine abnormality in PCOS. Before this hypothesis
can be understood an explanation of normal ovarian regulation is
needed.
2
1.1 REGULATION OF FEMALE REPRODUCTION
1.1.1 Historical background
The mysteries of reproduction have baffled scientists for
centuries. Each new discovery seems to have revealed only more
complex questions. The earliest studies of the growing embryo
were recorded by Hippocrates. It was not until the 17th century
though and the development of the microscope, that the origins of
the embryo were revealed. Initial findings were misleading. Hamm
and Leeuwenhoek observed the sperm for the first time in 1677
and thought they saw within it a tiny but complete human. The
presumed role for the female was thus simply to provide the womb
to nurture this growing fetus. A century passed before
Spallanzani showed in 1775 that both sperm and egg were required
for an embryo to develop.
The last 150 years however have seen the most rapid advances
in the understanding of reproduction. The cell theory, stating
that the body is composed of cells and cell products, was
established in 1839 by Schieden and Schwann and the discovery of
chromosomes and the principles of genetic inheritance began to be
uncovered. The interaction between the egg, sperm and their genes
was established as the centre of the reproductive process.
However, it became clear that there were hormones which regulate
the egg's development which were of equal importance in
reproduction.
The ovary was known to be the source of the egg but workers
in the 19th century showed that it also had other functions. The
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existence of ovarian hormones was implied from the results of
experimental removal of the ovaries. This operation was
invariably followed by atrophy of the genital tract. Although
early workers attributed these findings to incidental causes such
as interference with the vasular supply (Hofmeier 1880) or nervous
connections (Sokoloff 1896) of the uterus, it was later
established that the ovary produced hormones and it was the
removal of these factors which caused genital regression. In
the late 19th century, isolated extracts of the ovary were used
successfully to reverse the atrophy of the genital tract in women
without ovaries thus confirming the existence of ovarian hormones.
However, it was much later that the pure oestrogen, oestriol, and
then the progesterone metabolite, pregnanediol, were purified from
urine (Marrian 1929). Extraction of the active hormones from the
ovary proved more difficult and numerous substances with differing
biological activity were found. Two steroid compounds,
oestradiol-17B (McCorquodale et al 1935) and progesterone
(Wintersteiner and Allen 1934), were the most potent ovarian
factors isolated. Subsequent studies established that these are
the main steroid hormones secreted from the ovary.
More recently a peptide hormone, inhibin, has been isolated
from the ovarian follicle. It is undoubtedly an important
regulator of gonadotrophins although its physiological role is
still being investigated (Chappel et al 1980).
The role of the brain in controlling reproduction was
illustrated in 193 6 by Marshall and Verney who showed that
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electrical stimulation of the rabbit brain resulted in ovulation
and pseudopregnancy. Numerous studies using more localised
stimulii subsequently revealed that two specific areas of the
brain were primarily involved; the hypothalamus and the pituitary
gland. Anatomical studies showed that these areas were closely
linked by nerve fibres in the pituitary stalk and the surrounding
blood vessels. The importance of this link in reproduction was
reportedly demonstrated by Hinsey in 1937. In these studies,
transection of the pituitary stalk in rabbits resulted in atrophy
of the ovary. Again more specific studies subsequently showed
that, for reproduction, the important part of the link was the
blood vessels around the stalk. A humoral substance was
postulated which could be released from the hypothalamus by
electrical stimulation, secreted into the portal vessels and
thence carried to the pituitary gland. This hypothesis was
proved when the hormone was eventually isolated and its structure
determined in 1971 (Matsuo et al). It was given the name
luteinising hormone releasing hormone (IHRH) and, as postulated,
its principle action was found to be on the pituitary gland.
The existence of pituitary factors involved in regulation of
reproduction was suggested in early experiments in which removal
of the dog pituitary gland caused atrophy of the testes. Further
evidence was obtained by Long and Evans (1922) who showed that ox
pituitary extracts caused luteinization of the ovaries of rats.
The source of these hormones (gonadotrophins) was identified as
the anterior part of the pituitary by Smith and Engle in 1927.
Then Fevold et al reported in 1931 that they had separated two
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anterior pituitary substances which had different actions on the
ovary; one promoted follicle development and the other
luteinisation. The names follicular stimulating hormone (FSH)
and luteinising hormone (LH) were thus applied. The development
of methods of radioimmunoassay in the last 20 years enabled
specific measurement of these hormones. Their precise role in the
control of the ovary in women has subsequently been studied in
detail.
A complex interaction has been demonstrated between the
ovarian hormones oestradiol, progesterone and inhibin, the
pituitary hormones LH and FSH and the hypothalamic hormone LHRH
(Figure 1.1). The evidence for these links, on which our current
understanding of ovarian control is based, is described in more
detail in the following sections.
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FIGURE 1.1
REPRODUCTION CONTROL PATHWAYS IN THE FEMALE
7
1.1.2 Anatomy of the hypothalamic - pituitary - ovarian axis
HYPOTHALAMUS
The anatomical relationship between the hypothalamus and
pituitary gland is shown in Figure 1.2. The hypothalamus is a
small area lying in the midline in the base of the brain. It
contains several aggregations of neurons, the hypothalamic nuclei;
each being concerned with specific control functions and
synthesising its own specific releasing hormone. Neurons from
these areas project axons down to the median eminence of the
hypothalamus where the nerve terminals then lie close to the loops
of the portal vessels. LHRH secreted from these neurons enters
the portal veins surrounding the pituitary stalk and passes
directly to the pituitary gland. Immunohistochemical techniques
using LHRH labelled antibodies in rats have localised the neurons
containing LHRH to be principally in the arcuate and para¬
ventricular nuclei and in the preoptic area (Fuxe et al, 1978).
Although not all workers have been able to confirm these
observations specifically, the variations may be explained by
species differences. The principle of more than one hypothalamic
nucleus being involved in LHRH secretion is generally accepted
(McCann and Moss 1975).
The blood supply to the part of the hypothalamus
principally concerned with LHRH neurons is directly from the
systemic circulation. The localisation of IHRH neurons at several
sites allows there to be a possible synaptic contact with numerous
other hypothalamic neurotransmitters. Animal studies have shown







but there are several collections of dopaminergic neurons within
the hypothalamus (Fuxe 1965, Fuxe et al 1978, Bjorkland et al
1973). In particular a cluster can be found in the arcuate
nucleus (Figure 1.3). Some of the nerve terminals from these
nuclei end at the portal vessels whilst others appear to synapse
with LHRH nerve terminals. LHRH neurons are also closely
associated with serotoninergic terminals (Fuxe and Hokfelt 1969)
and histaminergic neurons (Brownstein et al 1973) are found in
the median eminence. Since cholinergic terminals are found wide¬
spread in the hypothalamus (Schute 1970), acetylcholine may also
be involved in LHRH regulation. The endorphins are found in the
arcuate nucleus and median eminence in close association with LHRH
neurons (Yen 1980b). Whilst anatomical links do not necessarily
imply functional relationships, all these various neuro¬
transmitters may be involved in LHRH regulation. One which has
been more extensively investigated than most is dopamine. This is
discussed in detail in Section 1.1.3.
PITUITARY GLAND
The pituitary gland is small, weighing only 500 mg. Within
the anterior part of the gland are several cell types. In
particular, there are basophilic cells containing LH and FSH
(gonadotrophs). Synthesis and secretion of LH and FSH occurs from
these cells (Figure 1.2). As well as receiving a blood supply via
the portal veins, a rich supply from the systemic circulation also
reaches the anterior pituitary gland via the superior and inferior
hypophyseal branches of the internal carotid artery. The venous
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FIGURE 1.3
DOPAMINERGIC NEURONS IN THE ARCUATE NUCLEUS:





drainage which contains the secreted pituitary hormones is to the
systemic circulation.
OVARY
A normal ovary is shown in Figure 1.4. It is found within
the abdominal cavity and, in the adult, is about 2 x 3 cm in
size. Histologically it consists of stromal tissue containing
primordial follicles surrounded by glandular tissue. These pri¬
mordial follicles are formed in neonatal life and, under
appropriate gonadotrophin stimulation, these follicles mature.
Each contains a primary germ cell or oocyte. Surrounding the
oocyte is a layer of granulosa cells, a basement membrane and a
theca cell layer outside the basement membrane. The interactions
between steroid secretion from the granulosa and theca cells is
crucial in both follicular development and in feedback control
of the gonadotrophins. The details of steroid secretion are
discussed in more detail later.
In the regulation of the ovarian cycle, the hypothalamus,
pituitary and ovarian components cannot be separated. Nonetheless
for clarity the physiological relationships will be discussed
individually in the following sections.
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Figure 1.4 NORMAL OVARY








1.1.3 Hypothalamic regulation of gonadotrophin secretion
There is a general acceptance that LHRH is the principle
hypothalamic regulator of LH and FSH synthesis and secretion.
Neutralisation of the endogenous LHRH in monkeys using specific
antibodies results in the decline of gonadotrophin release
(McCormack et al 1977). The prompt initiation of the ovarian
cycle using exogenous LHRH in women with primary deficiency of
LHRH is an indication of the importance of LHRH in the human
ovarian cycle (Crowley and McArthur 1980).
ACTIONS OF LHRH
IHRH is a decapeptide, [ (Pyro) -Glu-His-Tryp-Ser-Tyr-Gly-Leu-
Arg-Pro-Gly-NH2]. The availability of a synthetic analogue has
enabled the physiological role of LHRH to be studied in detail.
In humans it causes a release of both LH and FSH (Kastin et al
1972, Yen et al 1972). More detailed studies using varying
amounts of LHRH identified that small doses increased the pool of
LH stored in the gonadotroph without initiating release whereas
large doses cause release of LH (Hoff et al 1979). These priming
and releasing actions of LHRH are dissociable and thus may be part
of separate control mechanisms. Further evidence to support this
theory is the differing response of the two pools of LH to
oestradiol. The latter tends to inhibit the releasing action of




Following the initial observations in rhesus monkeys
(Dierschke et al 1970), studies of LH secretion in women found
that it is secreted in discrete pulses. These have been shown to
occur at intervals between one and four hours (Midgley and Jaffe
1971, Yen et al 1972a) and variations in LH pulse amplitude and
frequency have been seen during the ovarian cycle (Santen and
Bardin 1973, Reame et al 1984).
The origin of the pulses is generally agreed to be the hypo¬
thalamus. Although clearly it is not possible to sample the
portal vein in humans, studies have been performed in monkeys.
Circhorial oscillations of LHRH were recorded (Carmel et al 1976).
More recent investigations using a sheep model demonstrated that
each LH pulse was associated with an LHRH discharge (Clarke and
Cummins 1982).
The physiological significance of a pulsed LHRH signal is
uncertain. A continuous infusion of LHRH in hypophysectomised
monkeys results in a dramatic fall in LH which can only be
restored by pulsed LHRH administration (Belchetz et al 1978). A
possible explanation involves the LHRH receptors on the
gonadotroph. Constant supplies of LHRH may cause desensitisation
of the target cells by receptor loss and the normal recognition
and processing of the LHRH+receptor complex may require
alternating periods of rest and activity (Knobil and Plant 1978).
When discussing the hypothalamic regulation of gonadotrophin
secretion, therefore, the pulsatile nature of the LHRH signal must
be considered. The frequency of the LHRH signal determines the
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frequency of the LH pulses. The pituitary response and hence the
amplitude of the LH pulses is modulated by the relative
sensitivity of the gonadotrophin pools.
DOPAMINE
Of the many hypothalamic neurotransmitters, the one most
frequently implicated in LHRH regulation is dopamine (3,4 di-
hydroxyphenylethylamine). Structurally DA is closely related to
another neurotransmitter, noradrenaline. In animal studies there
is evidence that these two catecholamines have contradictory
effects on LHRH secretion consisting of inhibition by DA and
stimulation by noradrenaline (McCann and Moss 1975, Drouva and
Gallo 1977, Fuxe et al 1978, Gallo 1978, Anden et al 1970, Negro-
Vilar et al 1982). In humans, the evidence for a regulatory role
for noradrenaline is less than convincing but the involvement of
DA in IHRH control seems more likely.
In normal women DA, infusion has been shown to decrease LH
secretion (Martin et al 1981; Judd et al 1978, Judd et al 1979;
Pontiroli, 1980) and also suppress spontaneous LH pulses (Martin
et al 1981). Similar LH inhibition follows L-Dopa treatment
(Lachelin et al 1977). The LH response to DA varies during the
menstrual cycle (Judd et al 1978) and can be modulated by
oestrogen therapy (Judd et al 1979).
However, DA antagonists metoclopramide, monoiodotyrosine and
domperidone have failed to demonstrate an alteration in LH
secretion in normal women (Quigley et al 1979; Quigley et al
1980; Anderson et al 1982a; Anderson and Tabor 1982b; Seki et al
1982; Murdoch et al 1984; Ho et al 1984) and in hypogonadal women
16
LH pulsatility was maintained despite DA receptor blockade
(Anderson and Tabor,1982).
A possible explanation for these inconsistent findings is
that in none of these studies were the detailed patterns of LH
pulsatile secretion determined. DA may modify the pulse patterns
of LH release and such changes would not be apparent in short term
studies.
In this section it has been shown that the major stimulator
of the gonadotroph is the hypothalamic releasing hormone LHRH.
This is released in pulses and has both priming and releasing
effects on the gonadotroph. In addition the neurotransmitter, DA,
has been demonstrated to be involved in the regulation of LHRH
secretion. Additional modulating factors of the hypothalamic-
pituitary axis are the ovarian steroids oestradiol and pro¬
gesterone and their role will now be examined further.
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1.1.4 Ovarian regulation of gonadotroph in secretion
Although LHRH is essential for the synthesis and secretion
of LH and FSH, the cyclical pattern of their release is regulated
primarily by the feedback effects of the two ovarian sex steroids,
oestradiol and progesterone. The daily changes in these hormones
observed during the ovarian cycle are shown in Figure 1.5 (Baird
1980).
EFFECTS OF OESTRADIOL
Oestradiol can either inhibit (negative effect) or stimulate
(positive effect) LH secretion. The negative effect is most
clearly illustrated in post-menopausal women who are oestrogen
deficient; high gonadotrophin concentrations in these women can
be promptly suppressed with oestrogen therapy (Nillius and Wide
1970). The positive feedback effect is illustrated physio¬
logically in the ovarian cycle (Figure 1.5). A sudden rise of
oestrogen just before ovulation is followed by a surge of LH.
These two feedback effects can further be demonstrated by giving
oestrogens exogenously to pre-menopausal women. Initial LH
inhibition is seen over the first few hours followed by an LH rise
about 48 hours later (Shaw et al 1975b, Baird et al 1977).
MECHANISMS OF OESTRADIOL EFFECTS
The mechanisms by which oestradiol modulates gonadotrophin
secretion are uncertain. Studies in rhesus monkeys have shown
that after ablation of the arcuate nucleus and the administration
of constant LHRH pulses, both positive and negative feedback
actions of oestradiol on the gonadotroph are maintained (Knobil et
18
FIGURE 1.5
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al 1980). This suggests that oestradiol modulates the
gonadotroph directly. In women, studies of the LH response to
LHRH during the menstrual cycle showed that the pituitary
sensitivity increased with rising plasma oestradiol concentrations
(Lasley et al 1975). As explained earlier, this may have
reflected changes in the proportions of stored and releasable LH
in the gonadotroph which were altered by oestradiol.
A hypothalamic site for oestradiol feedback regulation of
LHRH is possible. Oestrogen receptors have been discovered in
many parts of the rhesus monkey hypothalamus (Gerlach et al 1976).
However, a direct effect of oestradiol on LHRH secretion has not
yet been found.
EFFECTS OF PROGESTERONE
By contrast progesterone appears to have its principle
action on the hypothalamus. Administration of progesterone to
women has been clearly shown to reduce LH pulse frequency (El
Sheikh et al 1983, Soules et al 1984) which was presumed to
reflect a decreased LHRH pulse frequency. An independent action
of progesterone on the gonadotroph has not been found.
Physiologically, the interplay between oestradiol and pro¬
gesterone in gonadotrophin regulation is probably much more
complicated. In high dose it appears to enhance the negative
feedback effects of oestrogens whilst blocking the positive
effect (Spies and Niswender 1971). By contrast, low doses seem to
enhance the positive feedback effects of oestrogens (Liu and Yen
1983) .
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It seems therefore that the sex steroids have a controlling
influence on both the hypothalamus and the pituitary gland in
regulating gonadotrophin secretion. Hence it follows that
abnormalities of steroid secretion may be expected to cause
abnormal gonadotrophin concentrations by alteration of both the
frequency and amplitude of their pulsatile secretion. The source
of these steroids is the ovaries and specific sites of their
production will now be described.
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1.1.5 Ovarian cycle and steroid secretion
The functional unit in the ovary is the follicle. The egg
develops within it and the principle secretions of the ovary
originate from cells within and immediately around it. From birth
it is thought that a steady supply of primordial follicles enters
the active growth cycle until the menopause is reached and that up
to 15 follicles may develop each month. With adequate gonado-
trophin stimulation these follicles will increase in size (up to
10mm) but most (preantral follicles) will then regress. One in
each cycle (the dominant follicle) has been shown to develop until
ovulation occurs (Baird 1980). The hormone milieu at the
initiation of follicular growth has been considered to be the
crucial factor determining the development of this dominant
follicle - in particular a small rise in FSH (Figure 1.5) (Midgley
and Jaffe 1968). This dominant follicle accounts for most of the
ovarian steroid production and this is discussed below in greater
detail.
The synthesis and secretion of hormones from the dominant
follicle are illustrated in Figure 1.6. Theca cells around the
follicle were found to possess LH receptors and under LH
stimulation they secreted the androgens, androstenedione and
testosterone (Han et al 1974). Androstenedione in particular
enters the developing follicles where it is the precursor for
further steroid synthesis. In addition the theca cells account
for most of the androstenedione circulating in the plasma. A rise
in androstenedione coincident with the midcycle LH peak is further
22
FIGURE 1.6
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evidence to support the relationship between androstenedione and
IH in women (Abraham 1974, Judd and Yen 1973, Kim et al 1949).
Granulosa cells lining this follicle develop FSH receptors.
Under the influence of FSH they acquire an aromatase enzyme and
hence gain the ability to convert androstenedione to oestradiol.
The synergistic effect of oestradiol and FSH induces granulosa
cell proliferation resulting in further oestradiol secretion
(Dorrington and Armstrong 1979). The dominant follicle therefore
contains relatively high oestradiol concentrations. The preantral
follicles which have not been influenced by the FSH rise in the
early stage of the cycle do not acquire aromatase activity and
therefore cannot synthesise oestradiol. They thus retain high
intrafollicular androstenedione concentrations. It is thought
that this balance between androstenedione and oestradiol is
crucial for the continued growth of the follicle; low andro¬
stenedione relative to oestradiol being a prerequisite for
complete development to the preovulatory state (Hillier et al
1980).
Prior to ovulation the dominant follicle develops LH
receptors and can therefore respond to the preovulatory surge of
IH. This induces release of the egg and subsequent luteinisation
of the granulosa cells. The corpus luteum which then forms will,
under further stimulation by LH, secrete progesterone (Baird
1980). The observation of high progesterone concentrations in the
luteal phase of the cycle is indicative of luteal function. For
practical purposes this is considered to indicate that ovulation
has occurred.
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In summary therefore, some of the factors required for
folliculogenesis are: normal LH concentrations to stimulate andro-
stenedione secretion; FSH to stimulate aromatase activity and
allow the conversion of androstenedione to oestradiol; and the
correct balance of androstenedione and oestradiol to allow the
follicle to mature to the preovulatory state.
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1.2 PROLACTIN AND REPRODUCTION
In addition to the hormones described in the preceding
chapters which are the principal hormones known to regulate human
reproduction, another pituitary hormone, prolactin, may also be
involved in reproduction. Its place in ovarian control in other
species is not disputed but in humans a physiological role, other
than during lactation, has not been found. However under patho¬
logical conditions as well as during lactation, high prolactin
concentrations have a profound inhibitory effect on ovarian
function (McNeilly 1980). The links between the regulation of
gonadotrophins and prolactin are outlined below.
1.2.1 Hypothalamic regulation of prolactin secretion
DOPAMINE
Prolactin secretion from the anterior pituitary gland
differs from that of other pituitary hormones since its release is
under constant inhibition by a hypothalamic inhibitory factor.
This is generally accepted to be DA since administration of DA
(Leblanc et al 1976) or a DA agonist (Lachelin et al 1977) to
humans invariably depresses prolactin release. In addition, DA
antagonists promote secretion (Judd et al 1976).
DA receptors are found in the pituitary gland and they are
predominantly located on the lactotrophs (Goldsmith et al 1979).
Neurons in the arcuate nucleus release DA into the portal vessels
and the inhibitory effect is thought to be direct at the
lactotroph (Ben Jonathan et al 1977). Thus, although the sites of
DA neurons affecting LHRH and prolactin secretion are similar, the
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targets of action differ. LHRH is inhibited by DA modulation of
its release into the portal veins whilst prolactin is inhibited by
a direct pituitary action on the lactotroph.
A short loop feedback system is also thought to operate in
prolactin regulation. Retrograde blood flow in the hypothalamic-
pituitary vascular bed has been demonstrated (Bergland and Page
1978). Prolactin secretion from the lactotroph may therefore pass
back to the hypothalamus and regulate DA secretion directly. It
would thus follow that hypothalamic DA concentrations would be
elevated in association with hyperprolactinaemia.
LHRH
The hypothalamic releasing hormone LHRH, when given in
pharmacological doses, stimulated prolactin release. The rise was
small and again was of uncertain physiological relevance (Yen et
al 1980b, Casper and Yen 1981). Prolactin secretion has been
noted to be pulsatile (Ehara et al 1973, Backstrom et al 1982) and
synchrony between spontaneous pulses of LH and prolactin have been
recorded (Cetel and Yen 1983, Braund et al 1984). This may
possibly reflect a common pulse generator such as LHRH.
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1.2.2 Ovarian regulation of prolactin secretion
Oestrogens have a stimulatory effect on the lactotroph. In
women the oestrogen concentrations vary during the ovarian cycle
and prolactin secretion related to these changes has been
investigated. During the slow oestrogen rise over the first half
of the ovarian cycle there is no change in prolactin concentration
but a midcycle peak coincident with the oestrogen peak has been
observed (Ehara et al 1973, Aksel 1981, Backstrom et al 1982).
Additional evidence for the relationship between oestradiol and
prolactin is the effect of prolonged pharmacological doses of
oestrogen; prolactin synthesis and release in women was found to
be promoted (Yen et al 1974).
Animal studies suggested that oestradiol has a direct
pituitary action since it caused lactotroph hyperplasia and hyper¬
trophy (Meites et al 1972, Franks 1983). Although not firmly
established, it seems that oestrogens may affect prolactin
secretion by modulating DA regulation. In rats, oestrogen
receptors are present on the DA neurons in the arcuate nucleus and
hypothalamic DA content is inversely related to the oestrogen
status (Selmanoff et al 1976, Donoso et al 1967, Eikenberg et al
1977, Fuxe et al 1969). In addition, portal vein DA concentrations
may be decreased with oestrogen therapy (Ben Jonathan et al 1977)
resulting in hyperprolactinaemia.
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1.2.3 Other factors regulating prolactin secretion
Several other factors modulate prolactin secretion. The
hypothalamic releasing hormone thyroid releasing hormone (TRH)
causes prolactin secretion when given intravenously (Jacobs et al
1971, McNeilly and Hagan 1974) although whether this is of physio¬
logical significance is unknown. Prolactin is also released in
response to stress and sleep (Copinski et al 1975, Ehara et al
1973). Ingestion of high protein food causes prolactin release,
possibly as a result of ingestion of neurotransmitter substrates
affecting the hypothalamic control pathways (Ishizuka et al
1983,Quigley et al 1981b). The physiological significance of
these various modulating factors of prolactin secretion is unknown
but clearly they must be taken into consideration when evaluating
lactotroph function.
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1.3 RELATIONSHIPS BETWEEN GONADOTROPIN AND PROLACTIN SECRETION
It has already been shown that there are several factors
that have similar effects on both the gonadotroph and the
lactotroph. Oestrogens and LHRH stimulate secretion from both
whilst DA inhibits LH and prolactin release. Whether these
similarities have a physiological significance in women is not
known. Nonetheless a functional link between prolactin and
gonadotrophins is seen in hyperprolactinaemia both physiological
(during lactation) and pathological (pituitary tumours).
Hyperprolactinaemia, from whatever cause, is associated with
amenorrhoea. It may result from lactation, pituitary tumour or be
drug induced (Delvoye et al 1977, McNeilly 1980). In each case,
the resulting ovarian suppression is similar. However, the ovary
is not the site of the problem. It remains responsive to gonado¬
trophins since exogenous therapy was shown to induce ovulation
(Leyendecker et al 1980). An abnormality of gonadotroph function
was demonstrated in studies of LH secretion in hyperprolactinaemic
women. These were characterised by a decrease in LH pulses
(Glaiser et al 1984, Klibanski et al 1984) and an impairment of
the LH response to LHRH.
Hyperprolactinaemia may be only an associated phenomenon to
the gonadotroph dysfunction rather than the cause. However, the
evidence suggests that prolactin is more likely to be the culprit.
The DA agonist bromocriptine is now used widely in the treatment
of hyperprolactinaemia and by reducing prolactin concentration it
is highly effective in restoring ovulation regardless of the
underlying cause.
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The mechanisms by which hyperprolactinaemia alters
gonadotroph function are unknown. Studies in hyperprolactinaemic
women found an exaggerated fall in LH concentrations after DA
receptor blockade. This suggested that tonic LH inhibition by DA
may have been increased (Quigley et al 1979). These results taken
together with the factors discussed in the preceding sections,
offer strong evidence that prolactin and gonadotrophin secretion
are linked by complex interactions between LHRH, DA and
oestradiol. How this is related to PCOS is explained in the
following sections.
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1.4 POLYCYSTIC OVARY SYNDROME
1.4.1 Historical background
The history of polycystic ovary syndrome (PCOS) starts with
the ovary since it was the anatomical abnormality of the ovary
which was first described in 1844 by Chereau. These enlarged
pearly white ovaries with thickened capsules were thereafter
removed under the belief that they caused a spectrum of gynae¬
cological problems from dysmenorrhoea to menstrually related
epilepsy! By the turn of the century a more conservative approach
was usually adopted and wedge resection was advocated. The link
between the abnormal ovary and the typical clinical symptoms was
made in 1935 by Stein and Leventhalto whose names the syndrome was
subsequently applied (Stein and Leventhal 1935).
The clinical features that they described were amenorrhoea,
obesity, hirsutism and infertility. However, these symptoms are
variable. In a later review, Stein reported that many of his
patients had oligomenorrhoea rather than amenorrhoea, only 50%
were hirsute and the 10% incidence of obesity was not thought to
be greater than that of the general population (Stein 1945).
Similar findings are reported in later reviews (Yen 1980,
Goldzeiher 1981, Futterweit 1984). Given this clinical variation
the diagnosis has rested on the observation of the typical
appearance of the ovaries.
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1.4.2 The polycystic ovary
A typical polycystic ovary is shown in Figure 1.7.
Although classically enlarged with a smooth capsule and underlying
multiple cysts, the ovary may look macroscopically normal
(Goldzeiher 1981). On cross section though, a characteristic
appearance is revealed. Multiple small cysts (usually clOmm)
are found aligned around the outer margin of the ovary.
Histologically the capsule of the ovary, the tunica
albuginea, is thickened and may be 15 times wider than normal
(Goldzieher and Green 1962). Hyperplasia of the stromal theca
cells has been described but is not a consistent feature (Green
and Goldzieher 1965). In 1943, Fraenkel used the term
'hyperthecosis* in relation°polycystic ovaries. Although sometimes
thought to constitute a separate disease, hyperthecosis more
likely reflects a more severe form of the condition in which there
is excessive hyperplasia of the luteinized theca cells surrounding
the follicle (Futterweit 1984). These follicles have been found at
varying stages of maturation and atresia. The follicular cyst
walls are lined with granulosa cells which cure separated from the
theca cells by a basement membrane.
Biochemically the follicles were shown to be similar to
preantral follicles, i.e. follicular fluid has high andro-
stenedione and low oestradiol concentrations (Tanabe et al 1983).
Also the intraovarian and the serum androstenedione and
testosterone concentrations were elevated (Laatikainen et al
1980). In the absence of dominant follicle formation and hence a
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Figure 1.7 polycystic ovary
GROSS APPEARANCE a. Thickened capsule
b. Dense stroma




corpus luteum, the ovarian production of oestradiol and pro¬
gesterone remained low.
These ovarian features were originally thought to reflect a
single disease entity. However, with the development of specific
hormone assay techniques, it became apparent that several distinct
endocrinopathies may be associated with polycystic ovaries (Yen
1980). These include Cushing's syndrome, congenital adrenal
hyperplasia, hyperthyroidism, hypothyroidism and hyper-
prolactinaemia. Some early investigations of PCOS must have
unwittingly included a variety of different diseases and it is not
surprising that some of their results were therefore difficult to
interpret. Current studies now exclude patients with these other
specific problems and patients are now generally selected on the
basis of the biochemical features consistent with our present
understanding of the pathophysiology of the condition. This is
explained in detail in the following section.
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1.4.3 Pathophysiology of PCOS
In his review of 1945 Stein stated his opinion that PCOS
resulted not from a congenital, inflammatory or degenerative
disease but from a definite endocrine disturbance. Although this
has been confirmed by subsequent studies, the precise cause of the
disturbance remains unknown.
The histological appearances of the ovary with hyperplasia
of the theca cells suggests excessive stimulation of these
elements. Consistent with this finding is the observation that
the concentrations of the hormones produced by the theca cells,
androstenedione and testosterone, are elevated in PCOS (de Vane et
al 1975, Laatikainen et al 1980, Yen 1980). As described before,
LH stimulates these theca cells and therefore IH has been studied
in detail in PCOS. Not surprisingly, elevated concentrations of
IH were found. Early workers using bioassays for gonadotrophins
(McArthur et al 1958) revealed wide fluctuations in 'LH' activity.
More sensitive radioimmunoassay techniques have enabled these
patterns to be analysed in detail.
In PCOS concentrations of LH were found to be elevated
whereas FSH concentrations were low or normal (Rebar et al 1973,
Berger et al 1975, de Vane et al 1975, Baird et al 1977, Chang et
al 1982). The pulsatile nature of LH secretion in PCOS has also
been studied. The elevated mean concentrations were mainly due to
increased amplitude of LH pulses (e.g. Figure 1.8) whilst no
consistent frequency changes have been found (Rebar et al 1976,
Baird et al 1977). In addition, the gonadotroph was thought to be
hypersensitive to LHRH since exaggerated responses to exogenous
IHRH were observed (Katz and Carr 1976).
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FIGURE 1.8
EXAMPLES OF SERIAL LH DATA
Samples taken every 15 minutes for 6 hours
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This abnormality is not thought to be due to an inherent
pituitary defect since the normal negative and positive feedback
responses to oestradiol remained intact (Shaw et al 1975a, Rebar
et al 1976, Baird et al 1977). It is suggested that the increased
pituitary sensitivity to LHRH may be due to chronic oestrogen
stimulation. In normal women oestrogen administration enhanced
the LH/FSH respones to LHRH (Jaffe and Keye 1974). Additional
support for this theory was the strong positive corellation found
between concentrations of the two oestrogens, oestrone and
oestradiol, and LH concentrations in PCOS (de Vane et al 1975,
Lobo et al 1981). Oestrogen concentrations were also related to
the LH response to LHRH in PCOS (Rebar et al 1976).
LH secretion in PCOS can also be modulated in the normal
manner by exogenous progesterone and this may explain the fall in
LH concentrations which has been observed to follow an ovulatory
cycle (Baird et al 1977, Rebar et al 1976).
If the LH elevation in PCOS is due to excess oestrogen
stimulation, that implies that there must be abnormal oestrogen
concentrations in this condition. Studies have shown that
although oestradiol concentrations were normal, those of the
weaker oestrogen, oestrone, were elevated (Baird et al 1977, Rebar
et al 1976, de Vane et al 1975). The principal source of oestrone
in women is from adipose tissue where enzymes were demonstrated
which can convert androstenedione to oestrone (Siiteri and
MacDonald 1973). As discussed already, androstenedione
concentrations are elevated in PCOS. Since the ovary produces this
hormone acyclically in PCOS, the resulting oestrone concentrations
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are also chronically elevated. This is presumed to be the cause
of the increased gonadotroph sensitivity.
The clinical symptom of hirsutism in PCOS is a result of the
increased circulating androgens, in particular, androstenedione
and testosterone. Hirsutism, by definition, refers to the rough
quality of hair. Nonetheless, it is generally applied to women
when the quantity of hair is increased. In its worst form, the
normal male patterns of hair growth occur including a full beard.
Hair follicles are sensitive to changes in skin androgen
concentration although there is considerable variation between
individuals. Androstenedione and testosterone are metabolised in
the skin to the more potent androgen, dihydrotestosterone and this
latter hormone stimulates the coarse terminal hair growth (Price
1975).
An additional factor which aggravates the problem is thought
to be sex hormone binding globulin (SHBG) (Anderson 1974). When
bound to SHBG, androgens are inactive. Thus, when SHBG
concentrations are low, the relative androgenic activity at the
target organ is increased. One factor which determines the
concentration of SHBG is the proportion of oestrogens to
androgens. Relatively high androgen concentrations cause a
decrease in SHBG. Clearly with excess androgens in PCOS, it is
not surprising that SHBG and therefore the active unbound androgen
concentration is significantly raised (Hatch et al 1981, Yen
1980).
From the preceding evidence of the biochemical abnormalites
found in PCOS, a hypothesis has been formulated which links these
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observations and may be the explanation of the pathogenesis of the
condition (Rebar et al 1976, Baird et al 1977). It is illustrated
in Figure 1.9 and is summarised below.
Excessive LH stimulation of the theca cells results in
increased ovarian androgen production. High intraovarian
androgen concentrations block follicular growth and prevent
ovulation. High plasma concentrations of androgens cause
hirsutism and reduce SHBG concentrations thus aggravating the
peripheral androgenic effect. Conversion of androstenedione in
adipose tissue results in increased oestrone concentrations. This
sensitises the gonadotroph to LHRH so that further excess LH
secretion ensues. Being highly sensitive to oestrogen inhibition,
FSH release is suppressed. In the absence of a rise in FSH to
stimulate mature follicle growth, ovulation fails to occur.
More recently, a further factor has been implicated in the
possible pathogenesis of PCOS. Evidence has accumulated which
suggests that there is a hypothalamic deficiency of DA. This is
based on three observations: firstly there is a suggested
association between hyperprolactinaemia and PCOS, secondly DA
infusion has been shown to cause an exaggerated fall in LH
concentrations in PCOS, and thirdly a therapeutic role for the DA
agonist bromocriptine has been claimed. This evidence is
discussed in detail in Chapter 2.
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FIGURE 1.9


















CHAPTER 2: EVIDENCE FOR DOPAMINE DEFICIENCY IN
POLYCYSTIC OVARY SYNDROME
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2.1 PROLACTIN SECRETION IN PCOS
Since DA inhibits prolactin secretion, a deficiency would be
expected to result in increased prolactin concentrations. Mild
hyperprolactinaemia associated with PCOS has been reported in
several studies although the incidence is variable; 67% (Corenblum
and Taylor 1982), 44% (Buvat et al 1982), 22% (Carmina et al
1984). Variation in the definition of hyperprolactinaemia between
studies may explain the differing results. As discussed earlier,
many physiological events can elevate prolactin concentrations
above the normal range e.g. stress, food and sleep. Therefore a
single estimation of prolactin should not be used to diagnose
hyperprolactinaemia. In practice it is usual to determine the
basal prolactin concentration by taking several blood samples at
short intervals in order to exclude temporary factors affecting
the lactotroph. As stress may be induced by venepuncture, an
indwelling intravenous cannula is often used for sampling.
Carmina et al studied 4 0 patients who had the typical
symptoms of PCOS and were confirmed ultrasonically to have poly¬
cystic ovaries. They measured prolactin concentrations in 4 blood
samples taken at half hourly intervals via an indwelling intra¬
venous cannula. The mean of these samples was compared to those
of 2 3 normal women in the early follicular stage of the cycle.
Nine patients (20%) had mean prolactin concentrations greater than
the normal range.
Buvat et al studied 16 patients with clinical symptoms of
PCOS and laparoscopically confirmed polycystic ovaries. Three
blood samples were withdrawn at 15 minutes from an indwelling
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intravenous cannula at 8:00h, 12:00h and 16:00h. Each set was
pooled and assayed for prolactin. Seven patients had at least one
value greater than the normal range (44%) and four had two or more
elevated values (25%).
Corenblum and Taylor investigated 25 women with clinical
symptoms of PCOS. Blood samples were taken on three separate
occasions and hyperprolactinaemia was diagnosed if the prolactin
concentrations in at least 2 samples exceeded the normal range (16
control subjects).
Little consideration was given in any of these studies to
the complex nature of spontaneous prolactin secretion which has
been described earlier. This may explain the disagreement in
results and also casts doubt on the existence of hyperprolactin¬
aemia as a feature of PCOS. As hyperprolactinaemia has been a
principal factor in favour of the DA deficiency theory, the
evaluation of complex patterns of prolactin secretion in PCOS is
clearly indicated.
The responses of the lactotroph cells to stimulation depends
on the amount of prolactin stored in the pituitary and the
availability of this prolactin for release. This may be a more
sensitive indicator of changes(in lactotroph control than is
spontaneous secretion. Previous studies of lactotroph function in
PCOS have given conflicting results. Prolactin responses to TRH
in PCOS have been found to be either normal (Valkov and Dokumov
1977; Carmina et al 1984) or exaggerated (Falaschi et al 1980;
Corenblum and Taylor 1982). In these cases the responses were
found to be related to preceding prolactin concentrations. In a
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study using the dopamine antagonist Haloperidol, an exaggerated
reponse was seen which was confined to those patients who had
elevated basal prolactin concentrations (Falaschi et al 1980).
A factor not taken into consideration in these studies which
may explain the discrepancy in results, was recent ovarian
function. The link between oestrogen, DA and prolactin has been
discussed earlier and since oestrogen concentrations are high for
two weeks preceding an ovulatory cycle, a difference might be
expected between the lactotroph function of patients who have just
ovulated and those who were amenorrhoeic. Lactotroph stimulation
studies which consider this variable are needed.
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2.2 EFFECTS OF DOPAMINE AND DOPAMINE AGONISTS IN PCOS
2.2.1 LH secretion
In a study of eight patients with PCOS, Quigley et al
(1981a) demonstrated that a DA infusion promptly suppressed LH and
the magnitude of the fall correlated with the basal LH
concentration. The fall was significantly greater than that seen
in normal women in the early follicular phase of the cycle. This
increased sensitivity of the gonadotroph to DA was taken to be due
to a reduction of endogenous DA inhibition of LH secretion.
Suppression of LH secretion has also been reported during
treatment with the DA agonist bromocriptine. Following long term
bromocriptine (5mg daily for 3 months), a reduction in LH
secretion was observed in 13 of the 20 patients studied (Jaquet et
al 1980). This response coincided with a restoration of ovulation
in these subjects and it is therefore possible that the LH changes
reflect the effects of other hormonal changes due to ovulation
rather than a direct effect of bromocriptine. An attempt was made
in their study to examine the pulsatile nature of LH release.
However the long sampling interval and short total study period
used meant that accurate analysis of the pulse patterns could not
be made.
In a further study (Spruce et al 1984) 20 patients with
PCOS whose main complaint was hirsutism, were treated with bromo¬
criptine (7.5mg daily) for up to 1 year. A significant fall in LH
concentrations was seen after 3 months therapy and this fall was
maintained for 12 months. Again this coincided with a restoration
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of menstruation which may account for the LH changes as described
above. No attempt was made in their study to determine LH
pulsatility. The LH response to LHRH was found to be reduced
after treatment in both trials.
Pontirioli et al (1980) found that the acute administration
of bromocriptine resulted in a fall in LH concentration. This has
been taken as further evidence to support the hypothesis of
decreased hypothalamic DA activity in PCOS. However, there are
conflicting studies. Martin et al (1981) found that acute
administration of bromocriptine did not alter LH secretion. Also
when given as therapy to hyperprolactinaemic women, bromocriptine
does not block physiological LH secretion since ovulation readily
occurs (Thorner et al 1974, Strauch et al 1977, Klibanski et al
1984). Therefore, although LH secretion in normal women and
patients with PCOS can be partially inhibited by DA infusion, the
response to bromocriptine is variable.
One explanation for the confusion is the possible existence
of several different DA receptors (Kebabian and Calne 1979). It
may be that bromocriptine and DA act at separate receptor sites.
DA stimulates D1 and D2 receptors whereas bromocriptine mainly
stimulates D2 receptors. The sites of the various receptor types
in man is unknown but animal studies suggest that the presynaptic
receptors are D2 whereas the central postsynaptic receptors are
the D1 type. Prolactin inhibition is mediated via D2 receptors
and therefore is activated by both bromocriptine and DA. The
postsynaptic DA inhibition of LHRH would involve D1 receptors only
and hence the disparity in effects of bromocriptine and DAP. An
alternative possible explanation for the inconsistent effects of
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DA and DA agonists on LH concentrations is that in none of these
studies were the detailed patterns of LH pulse secretion
determined.
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2.2.2 Therapeutic effects of dopamine agonists
On the assumption that DA may be deficient in PCOS it was
logical to attempt to treat the condition with DA agonist therapy.
Following reports of single cases of therapeutic benefit from
bromocriptine, trials have been conducted which seem to confirm
the initial observations (Jacquet et al 1980,Spruce et al 1984).
Jaquet selected patients on the basis of the biochemical
abnormalities consistent with the proposed pathophysiology of PCOS
described earlier. Twenty patients were treated with 5 mg bromo¬
criptine daily for three months. Thirteen had restoration of
ovulation. The effect on hirsutism was not recorded.
In the study of Spruce et al 20 patients received 7.5 mg
bromocriptine daily for between 3 and 12 months. Regular
menstruation was restored in 12 of the 2 0 women and 11 of the 2 0
eventually noted an improvement in their hirsutism. This improve¬
ment was accompanied by decreases in androstenedione and
testosterone although the absence of a change in SHBG makes the
significance of the androgen change uncertain.
A major criticism of these trials is that they were not
controlled and so a placebo effect cannot be excluded.
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2.3 PROPOSED STUDIES
2.3.1 Studies of prolactin secretion in PCOS
The spontaneous secretion of prolactin in patients with PCOS
will be compared with that of normal women taking into
consideration the physiological variables such as the pulsatile
pattern of secretion and the changes due to stress, food and
sleep. In addition, the lactotroph reserve will be evaluated
using various stimulating agents and the responses will be related
to the preceding ovarian function.
2.3.2 Controlled trial of bromocriptine therapy
A double blind controlled trial will be reported to evaluate
the therapeutic effects of the DA agonist, BRC, on patients with
PCOS. The biochemical changes during therapy will be reported, in
particular those of LH pulse patterns.
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CHAPTER 3: STUDY METHODS
3.1 SELECTION OF PATIENTS
3.1.1 Diagnostic criteria
It will be clear from the preceding chapters that there is
no single diagnostic criterion for PCOS. Patients who were
selected for this study had biochemical features consistent with
the proposed pathophysiology of PCOS.
The single clinical feature required was infrequent or
absent ovulation dating from the menarche. Although obesity and
hirsutism were common features, their presence was not considered
to be essential for diagnosis. The biochemical criteria for
diagnosis were an elevated LH concentration with raised LH to FSH
ratio (>2:1) and androstenedione and testosterone concentrations
at or above the upper limits of normal. Other specific endocrino-
pathies were excluded. Visualisation of the ovaries and histo¬
logical diagnosis was not considered to be essential for diagnosis.
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3.1.2 Patients and controls
The patients studied were recruited from general
endocrinology or gynaecology clinics over a period of two years.
Their presenting symptoms were oligomenorrhoea, amenorrhoea,
infertility or hirsutism. The ages of the patients were 18- 32
years. The clinical and biochemical details of all the patients
studied are given in Table 3.1. Normal women were recruited as
control volunteers. They had regular menstruation and no
hirsutism. Their ages were between 18-34 years. No medication
was taken by any subject during the study. Local Ethical
Committee approval was obtained and informed consent was given by
all subjects.
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TABLE3.1:CLINICALA DBIOCHEMICALDETA LSFPA ENTSSTUDIED
*A=amenorrhoea 0=11garenorrhoea(6-12weeks) R=cycle<6weeks



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The rate of hair growth was measured photographically by a
modified method of Burgess and Edwards (1978). The area to be
measured (24x36mm) was shaved and a control photograph taken. A
second photograph was taken 5 days later. No hair growth could be
measured on the initial photograph, therefore the measured growth
in the second photograph was recorded as representing five days of
growth.
A glass slide was placed firmly over the skin to flatten
the hairs. A Nikon FM2 camera with a 105 mm macro lens and
extension ring was used. With the lens at maximum extension the
primary magnification was x 1 (i.e. life-size image). A small
electronic flash was mounted on an angular bracket at the front of
the lens and once the optimum flash position was established this
was retained throughout the trial. The camera was hand held and
with the lens at maximum extension the object distance was altered
until a sharp image was achieved. The negative was enlarged and
printed to a magnification of X3.85 (Figure 3.2) on an automatic
printer. The image distance was noted enabling precise
standardisation of subsequent prints.
From each print the number of growing hairs was counted. In
addition the total length of 10 hairs on each print was recorded
using dividers as described by Burgess and Edwards and hence the
growth could be calculated.
The error due to the depth of field of the lens was
determined by photographing and printing a 10 mm image 10 times.
The coefficient of variation of the method was 0.5%. The error in
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Figure 3.2 EXAMPLE OF 5 DAYS OF HAIR
GROWTH,
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measurement of growth rate was determined by 10 repeat measure¬
ments of 1 print and was 5% at 0.41 mm/day. All measurements were
made blindly and in random order by the same observer.
59
3.3 ASSAY METHODS
All samples were separated within 12 hours of the test and
were stored at -20°C until assay. Samples were assayed in
duplicate and mean values used. For the frequent sampling study,
all samples from one subject for LH and prolactin were assayed
together. In the dynamic tests of lactotroph function, all
samples from each test were assayed together.
Radioimmunoassay techniques were used to measure the
hormones in this study. This method depends upon the competitive
binding of an antibody with a standard quantity of radiolabelled
hormone and unlabelled hormone (the antigens). The latter is the
unknown concentration within the test sample. Excess antigen is
present in order to enhance the competition for binding sites.
The unbound antigen is separated from the immune complexes by the
addition of a second precipitating antibody. The radioactivity in
the precipitate is related to the amount of displaced labelled
antigen and hence the concentration of hormone in the test sample.
A standard curve is constructed by plotting logit B/Bo against log
concentration of the standard where B=amount of radiolabelled
antigen bound in the presence of standard amounts of unlabelled
antigen, and Bo= amount of radioactively labelled antigen bound in
the absence of unlabelled antigen. From the linear part of this
plot the unknowns can be read. Intra- and interassay coefficients
of variation can be determined by assay of pooled sera containing
concentrations of antigen covering the range of standards used.
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3.3.1 LH, FSH and prolactin assay
LH and FSH were assayed using standards WHO 68/40 for LH and
WHO 78/549 for FSH. The LH and FSH antibodies were obtained
from Dr K. Ferguson, Chelsea Hospital. Prolactin was assayed
using standard NIBSC 81/541 and the antibody was obtained from
RIA UK. The intra assay coefficients of variation were <7.5% and
<4.9% at 9.7 U/l and 25 U/l LH: and <12.1% and<7.0% at 4.0U/1 and
16.8U/1 FSH. The interassay coefficients of variation were <10.8%
and <11.4% for LH and <15% and <7% for FSH. The intra-assay co¬
efficient of variation for prolactin were <9.6% and <7.4% at
379 mU/1 and 1037 mU/1. The interassay coefficient of variation
was <13.0%. These variations are illustrated in Figure 3.3.
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FIGURE 3,3
INTER- AND INTRA-ASSAY VARIATION
Prolactin, LH and FSH concentrations of 3 different pooled human sera
were estimated 10 times in each assay. The mean (+ SD) of the pool in
each assay are shown.
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Routine laboratory radioimmunoassay techniques were used for
steroid assays.
Oestrone assay involved ether extraction prior to radio¬
immunoassay which used antibody obtained from Steranti Research
Ltd (Product Code E001) and radiolabel [2,4,6,7-3H]-oestrone
(Amersham International pic). The interassay coefficients of
variation were <8.8% and <5.9% at 352pmol/l and 764pmol/l.
Oestradiol was assayed using an i125 oestradiol direct
radioimmunoassay kit supplied by Steranti Research Ltd (Product
Code ER155). The interassay coefficient of variation was <6.6%
and <3.0% at 334 pmol/1 and 963 pmol/1.
Testosterone was measured by radioimmunoassay following
extraction with ether, using rabbit antibody (Steranti Reseach Ltd
Product Code A003) and [ 1,2.6,7-3H]-testosterone (Amersham TRK402)
as label. The interassay coefficients of variation were <9.4% and
<8.6% at 1.8 nmol/1 and 10.4nmol/l.
Androstenedione analysis involved ether extraction then
radioimmunoassay using antibody obtained from RIA Ltd (Product No.
1025) and [1,2,6,7-3H]-androstenedione as label. The interassay
coefficients of variation were <7.4% and <5.4% at 3.4 nmol/1 and
5.6 nmol/1.
The technique for measurement of SHBG was a saturation assay






The two sample t-test was used to compare mean incremental
changes of observations of two groups after treatment. The
significance of the difference between the means was determined by
estimating the t value (mean of the differences divided by the
standard error of the mean) and reading off the probability value
at n-1 degrees of freedom from the table of t distribution.
For comparison of the mean observations between two
different groups, the non-paired t-test was used. The t value was
calculated as the difference between the means divided by the
standard error of the difference between the means. The




When the data for analysis did not have a normal
distribution, non-parametric tests were used. Wilcoxon's rank sum
test (two sample test) was used to compare 2 groups of data. All
observations were ranked in order and the rank total for each
group was added separately. The probability value for difference




The difficulties of interpreting serial biological data
have been recognised (Yates 1981, Clifton and Steiner 1983,
Merrian and Wachter 1982). Two main problems were appreciated.
Firstly, there was imprecision in the methods of radioimmunoassay.
Random variations due to assay error may have been interpreted as
physiological pulses (false positive error) or may have masked
genuine pulses (false negative error). This problem was
particularly important when the original pulse amplitude was
small relative to the random assay error. The second problem was
that of the sampling interval and the total study period which
were necessarily limited for practical reasons. Using the method
of analysis employed in this study the shortest frequency
detectable was 60 minutes (sampling interval x4) and the longest
was 6 hours (total study period). The number of cycles in the
study period and the number of samples taken per cycle also
affected the analysis (Clifton and Steiner 1983, Veldhuis et al
1984).
Several different approaches have been made to the problem.
The most commonly employed analyses used threshold methods (Yen et
al 1972, Santen and Bardin 1973, Baird et al 1977, Merriam and
Wachter 1982) i.e. peaks were identified from features such as
height and shape. The 'frequency' was then determined by counting
the number of peaks occurring in the study period. These methods
were limited by the problems mentioned above. Whilst being
adequate methods for analysing sporadic events and correlating
events such as coincident LH and FSH pulses, their value for
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detecting cycles was restricted. A cycle detector programme
(Clifton and Steiner 1983) has been devised based on a variable
threshold method which offered some solution to the problem of
equating false positive and negative errors but was limited by the
requirement of relatively homogeneous amplitude pulses.
Alternative methods which depend on assumptions about the
distribution of data have been employed (Christian et al 1978).
The presence of peak skewed the distribution of the observed
values. The analysis depended on the separation of the peak
values from the normally distributed baseline. This method proved
to be insensitive when compared to threshold methods (Merriam and
Wachter 1982). Conventional methods of time series analysis have
been employed in studies in the cow (Rahe et al 1980) but it has
generally been assumed that since they were not applicable to the
analysis of irregular cycles, their value to the analysis of LH
data was limited. It had previously been assumed that LH
secretion was irregular although there was no basis for this
assumption.
For this study three methods of pulse analysis were applied.
The first two represented the methods most commonly employed at
the time:
1. For the analysis of prolactin series the more sensitive method
of Santen and Bardin was used. A pulse was defined as a rise
over two successive samples of greater than twice the co¬
efficient of variation of the assay. The amplitude of the
pulse was the difference between samples.
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2. For the analysis of serial LH data, Baird et al (1977)
considered a pulse to have occurred if two consecutive samples
(peak samples) were greater than the previous two samples
(basal samples) and the value of one exceeds the 95%
confidence limits of the mean of the two basal samples. The
magnitude of the pulse was measured by subtracting the mean of
the basal samples from the highest peak value.
3. The third method employed, time series analysis (in particular
spectral analysis), was chosen because it was felt that
detection of an underlying regular harmonic pattern in the
data may have been a better estimate of the physiological
signal than the threshold methods of pulse detection.
A spectral analysis of a time series is a decomposition of
the total variation in the series into harmonic components
represented by cyclic variations at frequencies corresponding to
l,2,3...n/2 complete cycles in time T (n = number of observations,
T = total study time). The highest frequency detectable
corresponds to a series of alternating high and low values; whilst
the lowest frequency includes any long-term trends extending
beyond the total period of observation. Estimates of these
harmonic components of variation are plotted as a periodogram e.g
Fig 6.4. Each ordinate represents the amount of variation in the
series attributable to a harmonic frequency represented by the
abscissa value. The usual null hypothesis is one of 'white noise'.
Informally this means that there are no important harmonic
components of variation, so that all periodogram ordinates should
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be equal, within the limits of statistical fluctuation. A more
formal definition of white noise is that the series consists of
the observed values of independent, identically distributed random
variables. A test of significance is available, the 'cumulative
periodogram test'. Less formally, 95% 1-sided tolerance limits can
be added to the periodogram to indicate which, if any, harmonic
components are important. Under white noise, each periodogram
ordinate lies above these limits with probability <0.05. The
periodogram ordinates are mutually independent. The mathematical
details of these methods are given in Priestley (1981); a more
elementary but incomplete account is in Chatfield (1980, Chapter
V) .
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CHAPTER 5: STUDIES OF PROLACTIN SECRETION IN PCOS
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5.1 SPONTANEOUS PATTERNS OF PROLACTIN SECRETION IN PCOS
5.1.1 Design of the study
Sixty-two patients with PCOS and 28 control subjects were
investigated. The clinical and biochemical details of these
patients are given in Table 3.1. All studies on menstruating
women, except the random samples, were performed in the early
follicular phase of the menstrual cycle (Day 2-7). In most of the
patients with oligomenorrhoea, ovulation in the preceding cycle
was determined by weekly blood sampling for estimation of plasma
progesterone until the onset of menstruation. Progesterone
concentrations greater than 20 nmol/1 were considered to indicate
ovulation. All patients classified as anovulatory had pro¬
gesterone concentrations less than 2 nmol/1 or had amenorrhoea for
at least 3 months before and 1 month after the study.
Random serum prolactin concentrations were estimated from 62
patients and 20 control women. Subjects in whom this was greater
than the upper limit of the normal reference range in our
laboratory (>450 mU/1) were studied further. An indwelling
intravenous cannula was inserted and prolactin estimations were
made then and again after 1 and 2 hours.
Twenty-eight patients with PCOS and 10 normal women had the
details of their spontaneous prolactin secretion assessed by a
frequent sampling study. They were admitted to the Investigation
Unit at 08:00h. An intravenous cannula was inserted into the
forearm and from 08:3Oh samples were withdrawn every 15 minutes
for 6 hours. Subjects rested supine during the study. Lunch was
taken at 12:00h.
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Four patients and 6 controls had hourly blood samples obtained
from an indwelling intravenous cannula overnight during sleep.
They were admitted at 18:00h after a meal and the cannula was
inserted at 19:00h. Subjects rested during the evening and
retired to bed at about 20:30h after a hot drink. All were
observed to be asleep during most of the night.
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5.1.2 Results
Two of the 62 patients had persistent, mild elevation of
prolactin concentration when cannulated samples were taken
(>450<1500mU/l). The multiple sampling study was performed on one
of these patients (Table 8.1, subject 42). Her mean prolactin
concentration was elevated over each two hour study period
compared with that of the PCOS group (t = 11.65, 7.35, 6.27,
p<0.001). The clinical features and other biochemical measure¬
ments of these individuals were not unique.
The mean random prolactin concentrations of the remaining
patients are shown in Table 5.1. When several samples had been
taken from one subject, the mean was considered. The distribution
of results was skewed to the lower concentrations so non-
parametric tests were used for comparison. There was no
significant difference between the patients and the controls. At
least one random prolactin estimation was greater than the
laboratory normal range (450mU/l) in 19 of 62 patients and six of
28 controls (differences not significant).
More accurate basal prolactin estimations were obtained from
the multiple sampling studies (Table 8.1). Fluctuations occurred
in all series suggestive of pulsatile secretion. Pulses were
defined by the more sensitive method of Santen and Bardin (1973)
rather than the method of Baird et al (1977) which was
specifically applied to the interpretation of LH series. There was
no obvious regular pattern in these pulses. The mean number of





No. of subjects 60 28
Mean mU/i 313 319
Range mU/l 100-945 118-881
(all samples) Differences not significant
Actual values (mean if several random samples from one subject)
PCOS Controls
105 309 315 305 387 435 355 193 310
313 483 290 185 190 323 118 550 241
218 380 516 352 195 670 371 881 191
342 285 155 390 170 195 219 239 221
267 170 385 216 350 467 214 272 282
237 205 490 244 436 255 201 577 272
110 342 308 135 230 503 212 224 223
362 485 201 205 225 245 548 238 320
377 556 410 445 183 325 476 475
451 303 318 277 177 322 196 323
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controls was 2 per 6 hours (range 1-4). These are illustrated in
Figure 5.1.
Also illustrated are two variant patterns detected
frequently in the series; initial prolactin elevations and
increments after lunch. For comparison of the changes in
prolactin concentrations within individual series, an initial
elevation was considered to have occurred if the mean of the first
2 hours of the study exceeded the 95% confidence limit of the mean
of the middle two hours of study. Similar criteria were used to
define a post-prandial rise in prolactin concentration by
comparing the means of the middle and last two hours of the study.
(1) Initial prolactin elevations are demonstrated in Figure 5.1.
Such changes were seen in 21 of 28 patients and 9 of 10
controls (difference not significant). The prolactin fall was
completed by 2 hours after cannulation in all subjects.
(2) Prolactin increments after lunch were seen in 14 of 28
patients and 3 of 10 controls (difference not significant).
Because of these observations, the mean prolactin
concentrations were compared after dividing each 6 hour study
period into 3x2 hour series. The results are shown in Table
5.2. There was no difference between the patients and the
controls in any of these groups.
No difference was found related to recent ovulation.
The four patients and six controls who were studied over¬




EXAMPLES OF THE INDIVIDUAL SPONTANEOUS PATTERN
OF PROLACTIN SECRETION OVER 6 HOURS TO SHOW:
(a) SPONTANEOUS FLUCTUATIONS






Spontaneous prolactin fluctuations seen in all subjects
Q-
Initial prolactin elevation was seen in 25 (89%)







Post prandial prolactin elevation
was seen in 11 (39%) of patients and 2 (20%) of controls




MEAN PROLACTIN CONCENTRATIONS TAKING ACCOUNT OF THE
INITIAL ELEVATION (0-2 h), POSTPRANDIAL ELEVATION (4-6 h)





No. of subjects 28 6t 151 10
Mean (range) mU/l
0-2 h 228 (108-417) 199 (108-280) 243 (143-417) 220 (105-333)
2-4 h 177 (100-424) 151 (100-205) 180 (104-424) 157 (100-226)
_cCD1*3* 204 (103-494) 201 (146-275) 214 (103-494) 178 (101-374)
Differences not significant
^Ovulation not determined in all subjects
7 7 a
FIGURE 5.2




In this study, the incidence of mild hyperprolactinaemia was
two in 62 patients. In the remaining subjects, no abnormality of
prolactin secretion was found. These two subjects may have the
unusual condition of 'hyperprolactinaemic PCOS1 described by Yen
(1980). He considers this to be a syndrome of unknown and
probably separate aetiology from PCOS. Therefore the patients
were excluded from the study group because the aim of the
investigation was to examine the lactotroph function as it related
to the aetiology of PCOS. However if these patients simply
reflect a more severe form of the disease their results should be
included. The data were reanalysed accordingly but no significant
difference was found.
The discrepancy between the results of this study and the
earlier findings (Corenblum and Taylor 1982, Buvat et al 1982,
Carmina et al 1984) may be explained by the problems of both
patient selection and the diagnosis of hyperprolactinaemia.
Because of the nature of their symptoms, patients with PCOS do not
always seek medical attention. Hence neither this study nor the
others can represent the true incidence of hyperprolactinaemia.
The patients in this study were referred for further investigation
from general endocrinology and gynaecology clinics over a period
of two years but it is unlikely that all individuals with PCOS
were seen. Some may have been referred to a separate research
clinic for the investigation of hyperprolactinaemia. To examine
this possibility, the records of 102 women aged between 16 and 40
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years seen for hyperprolactinaemia over the same period were
reviewed. Only two patients were found who fulfilled the criteria
for diagnosis of PCOS used in this study. Both had the additional
symptoms of galactorrhoea and neither had hirsutism. They
responded to bromocriptine with regulation of menstruation.
Inclusion of these subjects in this series increased the incidence
of hyperprolactinaemia in PCOS to 7%.
In addition there was a potential inconsistency in the
diagnosis of PCOS which determined patient selection. As
described earlier (Section 2.1), Corenblum and Taylor relied on
clinical features alone and the studies of Carmina et al and Buvat
et al used clinical and ovarian observations for diagnostic
purposes rather than the biochemical findings. Despite the
differences in diagnostic criteria, their mean basal steroid and
gonadotrophin concentrations were consistent with those in this
study. It seems probable therefore that we were dealing with the
same pathological condition.
Variation in the definition of hyperprolactinaemia between
studies may explain the differing results. As discussed earlier,
many physiological events can elevate prolactin concentrations
above the normal range e.g. stress and food and sleep. Therefore
a single estimation of prolactin should not be used to diagnose
hyperprolactinaemia. In this study the diagnosis was made only if
all three estimations were above the normal reference range.
Carmina et al used the mean of a similar series and application of
their method to the current data did not alter the incidence of
hyperprolactinaemia. Applying the definition of Buvat et al (mean
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of three samples taken at 15 minute intervals) the incidence of
hyperprolactinaemia in this study rose to 5%, and using the
definition of Corehblum and Taylor (2 of 3 random samples greater
than the normal range) the incidence became 13%. In the latter
study, all but two of the 12 hyperprolactinaemic patients had at
least one prolactin estimation within the normal range. Therefore
by the definition used here persistent hyperprolactinaemia
occurred in only two of their 18 patients.
Intermittent prolactin elevations were noted in both the
patients and controls. As similar increases were present in both
normal women and patients, they cannot reflect a specific
abnormality of PCOS. The spontaneous fluctuations of prolactin
may reflect a regular pulsatile pattern of secretion similar
to that found for LH (see Chapter 6) but such a pattern could not
be determined under the experimental conditions used here.
However, an abnormality of pulsatility seemed unlikely since the
mean prolactin concentration was not affected. Furthermore, the
physiological significance of such an abnormality in relation to
ovarian regulation is uncertain since the pattern of prolactin
secretion does not appear to affect ovulation (Klibanski et al
1984) .
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5.2 LACTOTROPH RESPONSE TO STTMUIATION IN PCOS
5.2.1 Design of the study
The clinical and biochemical details of the patients in
these studies are given in Table 3.1. Ovulation in the preceding
cyle was determined as in Section 5.1.1.
(1) DOMPERIDONE TEST
The reponse of the lactotroph to DA antagonists was tested
using domperidone (Janssen Pharmaceuticals) which blocks DA
receptors (Pourmand et al 1980). This drug does not cross the
blood brain barrier so effects the median eminence of the
hypothalamus without having widespread actions in the central
nervous system. It is therefore devoid of the side effects
commonly associated with other DA receptor blocking agents
such as metoclopramide which can enter the central nervous
system. Since the lactotroph response to domperidone and
metoclopramide are similar (Pourmand et al 1980, Judd et al
1976), the former drug was selected. Seventeen patients with
PCOS and 13 control women were studied. After an overnight
fast, an intravenous cannula was inserted into the forearm at
08:3Oh and blood was taken then and after 15 minutes for basal
estimation of prolactin. Domperidone (lOmg) was given
intravenously and further samples of blood were taken after
15, 30, 45, 60, 90 and 120 minutes for prolactin estimation.
No side effects were noted.
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(2) THYROID RELEASING HORMONE (TRH) TEST
This test has been described in Jacobs et al (1971).
Intravenous administration of the synthetic preparation of TRH
(Roche) to normal subjects induces a prompt rise in prolactin;
the magnitude of which reflects the amount of prolactin stored
and available for release in the lactotroph. Eleven patients
with PCOS and 8 control women were studied. An intravenous
cannula was inserted into the forearm at 14:00h and basal
serum samples were obtained then and after 15 minutes.
Thyroid releasing hormone (200ug) was given intravenously and
blood was obtained after 20 and 60 minutes for prolactin
estimation. The typical side effects of flushing and a
metallic taste were noted by some individuals.
(3) LUTEINISING HORMONE RELEASING HORMONE (LHRH) TEST
The ability of LHRH to effect a release of prolactin was
discussed in Section 1.2. A synthetic analogue (Ayerst
Pharaceuticals) was used in this study. The response of the
lactotroph to LHRH was tested immediately after the multiple
sampling study described in Section 5.1.1. After the last of
the multiple samples was taken (14:3 Oh) LHRH 100 ug was given
intravenously and further bloqd samples were taken after 20,
40 and 60 minutes for prolactin estimation.
(4) INSULIN STRESS TEST
The mechanism by which stress induces a rise in prolactin is
uncertain but is probably mediated via the hypothalamus. In
order to determine the lactotroph response to stress, insulin
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is given to produce hypoglycaemia. The presence of prolactin
release following stress is physiological and the magnitude of
the response represents the quantity of prolactin available
for release in the lactotroph.
Hypoglycaemia was induced with insulin in eight patients with
PCOS and seven normal women. They were admitted to the
Investigation Unit at 08:00h after an overnight fast. All had
a recent normal electrocardiograph. Soluble insulin O.lU/Kg
body weight was given to lower the blood glucose concentration
to less than 2nmol/l. At this point all had the typical
symptoms of sweating and lightheadedness. Blood samples from
an indwelling intravenous cannula were obtained 15 minutes
before and at the time of insulin injection and again after
30, 60, 90 and 120 minutes.
At the time of these studies, a blood sample was also taken
for estimation of oestrone, oestradiol, androstenedione,
testosterone, sex hormone binding globulin (SHBG), LH and FSH.
When more than one test was performed on an individual they were
separated by at least 24 hours.
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5.2.2 Results
The results of studies using the lactotroph stimulating
agents domperidone, TRH and LHRH are given in Table 8.3 and are
illustrated in Figures 5.3, 5.4 and 5.5. The prolactin responses
to domperidone and TRH were clearly related to the preceding
ovarian function. After an ovulatory cycle, a normal response was
seen whereas a blunted response followed a period of anovulation.
Responses to LHRH were comparatively small and there was no
difference between the groups.
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FIGURE 5.3
PROLACTIN RESPONSES TO DOMPERIDONE






Ovulatory PC0S (n = 6)
Normal (n = 13)
Anovulatory PC0S (n = 11)
30 45 60 90
Minutes after Domperidone
Difference from normal ** P <0.001 Difference from ovulatory
PCOS
xx P < 0.02
£ P < 0.001
^ P < 0.01
++ P < 0.02
+ P < 0.05
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FIGURE 5.4







^ Controls n = 8
^.Ovulating PCOS n = 4
Anovulating PCOS n = 7
20 60
Minutes after TRH




PROLACTIN RESPONSE TO LHRH (100^9 IV)
(mean ± SE)
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Insulin induced hypoglycaemia caused a prolactin increase
and again this was found to relate to recent ovarian function.
The prolactin response in PCOS was blunted in the 6 patients who
were amenorrhoeic at the time of the study (Figure 5.6). A
seventh patient who had ovulated, had an apparently exaggerated
response and her basal prolactin concentration was high (400
mU/1). Basal prolactin concentrations were not related to the
maximum per cent increase in any of the other dynamic tests in
these studies.
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609 Minutesaft rins lin
—OvulatoryPCOSn Controls=7 AnovulatoryPCOS 120n=6
Differencefromnor al**p<0.01
Basal concentrations of testosterone, androstenendione,
oestrone, oestradiol, SHBG, LH and FSH determined at the time of
the study are shown in Table 5.3. As expected, high
concentrations of testosterone, androstenedione, oestrone and LH
were found whereas oestradiol and FSH concentrations were normal.
SHBG was low but the difference overall was not significant.
Similar biochemical changes were seen in all patients but the




BASAL STEROID AND GONADOTROPHIN CONCENTRATIONS AT THE
TIME OF STUDY (mean ± SE)
PCOS Controls
All Ovulatory Anovulatory
No. of subjects 28 6* 15+ 10
Testosterone (nmol/l) 3.9 ± 0.2V 3.7 ± 0.6 4.1 ± 0.3*** 2.8 ± 0.2
Androstenedione (nmol/l) 17.3 ± 1.5** 21.1 ± 5.3 17.8 ± 1.5** 11.5 ± 1.2
Oestrone (pmol/l) 368 ± 25*** 330 ±146 425 ± 25*.* 227 ± 18
Oestradiol (pmol/l) 184 ± 20 138 ± 13 210 ± 32 152 ± 20
Sex hormone binding
globulin (nmol/l) 37 ± 21 43 ± 7 27 ± 1.8** 63 ± 11
LH (U/l) 12.7 ± 1.2*** 8.4 ± 0.9** 16.3+ 1.8*** 4.9 ± 0.3
FSH (U/l) 4.3 ± 0.3 4.1 ± 0.4 4.6 ± 0.2 3.6 ± 0.4
Differences from normal **p<0.001
**p<0.01
^Ovulation not determined in all subjects
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5.2.3 Discussion
Unlike earlier reports, these studies have failed to show an
abnormality of lactotroph reserve specifically related to PCOS.
However, none of the earlier studies took into account the
preceding ovarian cycle in the patients. It was clearly shown
here that recent ovulation determined the lactotroph response to
stimulation. Other studies of patients with various anovulatory
conditions such as hypothalamic hypogonadotrophic amenorrhoea
(Quigley et al,1980), normogonadotrophic secondary amenorrhoea
(D'Agata et al,1981), and normogonadotrophic and hypogonadotrophic
primary amenorrhoea (Batrinos et al, 1981) have revealed similar
blunted prolactin responses to dopamine blockade. It seems
probable therefore that the blunted prolactin responses seen in
PCOS reflect anovulation rather then any specific lactotroph
abnormality in PCOS.
The reasons why ovulation may alter lactotroph function are
unknown. Oestrogens are probably involved as has been discussed
earlier. In women who had ovulated there was a high concentration
of oestradiol in the two weeks preceding the study which may have
stimulated the lactotroph. The absence of this in anovulatory
women may be the reason for the blunted lactotroph to stimulation.
High concentrations of progesterone are also seen in the
luteal phase and its possible role in the alteration of lactotroph
response to stimulation has yet to be determined.
An alternative explanation for the different results of the
ovulatory group is that they may have constituted a separate or
less severe disease group. To some extent this was confirmed by
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the basal steroid and gonadotrophin concentrations (Table 5.3).
The effect of ovulation on the biochemistry in PCOS has already
been discussed and it is clear that improvement may be observed
immediately after an ovulatory cycle. By waiting for the early
follicular phase in oligomenorrheic patients, it was therefore not
surprising to find less biochemical aberration in these subjects.
When the biochemical parameters used for the initial diagnosis
were analysed, no difference was found between the ovulatory and
anovulatory patients.
Obesity is a common feature of PCOS. In this study the mean
weight of the patients was 26% + 33% above the average (Life
Extension Institute of New York City). Studies of prolactin
secretion in massively obese women (103-104% above Ideal Body
Weight) have shown either normal responses to TRH and the DA
antagonist, sulphiride, (Sannia and Benna 1982) or blunted
responses to TRH and absent response to insulin stress testing
(Kopelman et al 1980). In the latter study the abnormal
reactions remained after weight reduction suggesting an underlying
hypothalamic disorder of prolactin regulation in some women with
previous obesity, irrespective of their weight at the time of the
study. This could be an explanation for the results of the study
reported here. However, no correlation was found between the
patient's weight and the lactotroph response.
The hypothesis being tested in this study has made the
assumption that the origin of the hypothalamic DA which may
regulate LHRH secretion is similar to that which inhibits
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prolactin secretion. Figure 1.3 illustrates the different ways by
which DA may modulate LHRH secretion. In man the precise neurons
involved with LHRH regulation in the median eminence have not been
distinguished from those which release DA into the portal vessels
and hence inhibit prolactin release. It is possible therefore
that a DA deficiency effecting LHRH secretion may not alter the
DA regulation of the lactotroph. This might explain the lack of
alteration of lactotroph function in PCOS observed in this study.
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CHAPTER 6: STUDIES OF LONG-TERM DOPAMINE AGONISTS IN POOS
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6.1 DESIGN OF THE STUDY
A previous study (Spruce et al 1984) of the therapeutic
effects of the DA agonist bromocriptine in PCOS found that 75% of
the patients had improved menstrual frequency and 55% had improve¬
ment in their hirsutism. Anticipating that a similar response
would be seen in a controlled trial, it was calculated from the
statistical tables of Casagrande et al (1978) that with 22
patients receiving either bromocriptine or placebo, there would be
an acceptable probability (p<0.05) of a significant result.
Patients were allocated randomly to either bromocriptine or
placebo. The placebo was an inert compound of similar appearance
to the bromocriptine tablet and was provided by Sandoz UK Ltd.
Allocation of the patients to each group was unknown to patient or
observer. Twenty-two patients were recruited over a period of one
year. All had the main complaint of hirsutism. To confirm this
objectively the scoring system of Ferriman and Gallwey (1961)
[adapted by Hatch et al (1981)] was used. In this study, nine
areas at which hair growth is hormonally dependent were graded 0-
4, according to the amount of hair present. These areas were upper
lip, chin, chest, upper back, lower back, upper abdomen, lower
abdomen, upper arm and upper leg. Since only 5% of premenopausal
women have total scores of greater than 8, this was taken to be
the criterion for diagnosis of hirsutism. The clinical and
biochemical details of the patients are given in Table 3.1.
In all patients the drug was given in slowly increasing dose
from 1.25 mg to 7.5 mg daily over two weeks. Patients were
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assessed at the start of the trial and again after 6 and 12 months
of therapy.
Eleven patients received bromocriptine; 7 completed 12
months therapy, 1 defaulted for social reasons and 3 because of
side effects. Eleven patients received a placebo; 9 completed 12
months, 1 defaulted for social reasons and 1 because of side
effects. The side effects were those recognised to occur with




Hirsutism was assessed subjectively as 'worse', 'unchanged'
or 'improved' (sufficient to warrant a request for continuation of
treatment after the trial). Objective assessment of the response
was by the photographic methods described in Section 3.2. Two
areas were measured on each subject; the sideburn or chin and the
midline subumbilical area. These were the sites which caused
greatest concern. The precise areas were recorded relative to
fixed anatomical landmarks such as the ear or umbilicus so that
the measurements could be accurately repeated.
6.2.2 Results
Results of the subjective assesment of hirsutism are shown
in Table 6.1. Two patients on bromocriptine reported a marked
improvement in hirsutism but despite this observation both still
needed to shave daily. The results of the photographic measure¬
ments are shown in Table 8.4 and 8.5, and are represented
graphically in Figures 6.1 and 6.2. There was no significant
difference in the change of hair growth rate or numbers of hairs
between the groups. The individuals who reported an improvement
in hirsutism are identified and no change was seen in the photo¬
graphic assessments of these patients. These patients are
discussed further in the next section.
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TABLE 6.1
SUBJECTIVE ASSESSMENT OF HIRSUTISM CHANGE
Bromocriptine Placebo
n = 11 n = 11
Completed trial 7 9
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subjects who reported marked improvement
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FIGURE 6.2
NUMBER OF HAIRS GROWING DURING TRIAL
(area 24 x 36 mm)
12 0 6 12
Months of treatment










6.3 MENSTRUAL FREQUENCY STUDY
6.3.1 Methods
The change in frequency of menstruation between the 6 months
preceding the trial to the last 6 months of therapy was compared
between the two groups.
6.3.2 Results
There was no statistically significant difference between
the alteration in menstrual frequency of the groups (Table 6.2).
Oneof 2 subj ects who reported improvement in hirsutism had more
frequent menstruation.
The clinical and biochemical features of these two patients
at the time of selection for the trial were not unusual (subjects
16 and 42 in Table 3.1). However, subject 42 was found
subsequently to have persistent mild hyperprolactinaemia and was




Number of periods per individual in 6 months
BROMOCRIPTINE (n = 7) PLACEBO (n = 9)
Subject 6 months Last 6 months Subject 6 months Last 6 months
No. pretrial trial No. pretrial trial
42 4 6 28 0 0
39 3 4 33 2 5
16 5 3 36 4 0
1 1 5 23 5 5
41 2 2 37 4 5
49 1 5 48 5 6






In order to evaluate any change in gonadotroph function
which may follow DA agonist therapy, the frequent sampling study
outlined below was performed on most subjects.
Patients were admitted to the Investigation Unit at 08:00h.
An intravenous cannula was inserted into the forearm and from
08:3Oh samples of blood were withdrawn every 15 minutes for 6
hours. Subjects rested supine during the study. After the final
blood sample was taken a bolus of lOOug LHRH was given intra¬
venously. Further samples were taken after 20, 40 and 60 minutes
to determine the gonadotroph response to stimulation. In oligo-
menorrheic women, these studies were performed in the early
follicular phase of the ovarian cycle and ovulation in the
preceding cycle was determined as described in Chapter 5.
6.4.2 Results
The multiple sampling study was performed on 14 subjects
altogether; 7 taking placebo were studied on 3 occasions and 1 was
studied twice before defaulting because of side effects. Six
subjects on bromocriptinewere studied on 3 occasions and 4 had
pretrial studies only (all the latter defaulted on therapy). The
results are shown in Table 8.6 and summarised in Table 6.3.
There was no statistically significant difference in the
change in mean LH, FSH or LH:FSH ratio between the bromocriptine
and placebo groups. The maximum response of LH and FSH to LHRH
was also unaffected by treatment.
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TABLE 6.3
GONADOTROPHS CHANGES DURING TRIAL (mean values)
0
BROMOCRIPTINE (n = 7)





LH u/l 11.8 10.5 11.5 9.4 9.2 8.9
FSH u/l 4.0 3.4 3.7 4.2 4.2 4.0
LH : FSH 3.0 3.0 3.1 2.3 2.5 2.2
Max LH to LHRH 40 36 52 28 32 27
Max FSH to LHRH 3.2 2.7 2.3 2.6 3.7 3.2
Number of pulses LH 2.8 3.8 3.2 3.6 3.3 3.4
Pulse amplitude 2.6 3.8 3.3 2.5 3.3 2.3
Differences not significant
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No change was found in LH pulse amplitude or frequency in
either group when analysed by the methods of Baird et al (1977).
Spectral analysis of individual series failed to reveal




At the start of the trial and after 6 and 12 months a single
blood sample was taken for estimation of the following; andro-
stenedione, testosterone, oestradiol, oestrone and SHBG.
6.5.2 Results
The biochemical changes in each group are shown in Table 8.7
and summarised in Table 6.4. A significant fall in andro-
stenedione was seen in each group but there was no difference
between the changes in the bromocriptine and placebo groups.
There was a difference in testosterone concentrations between the
groups at the initial assessment. This difference was not seen in




STEROID CHANGES DURING TRIAL (mean values)
BROMOCRIPTINE (n = 7) PLACEBO (n = 9)
0 6 months 12 months 0 6 months 12 months
Testosterone nmol/l 4.3 3.2 3.7 3.2t 2.9 3.1
Androstenedione
nmol/l 21.0 10.2 12.4 15.7 11.3 9.0
Oestrone pmol/l 342 294 329 388 287 342
Oestradiol pmol/l 183 151 227 141 155 173
SHBG nmol/l 28 36 34 40 49 44
Comparison of basal concentrations between groups (non-paired t test)
^
p < 0.05 No significant differences in incremental changes between groups
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6.6 DISCUSSION
This trial has failed to find a therapeutic role for bromo¬
criptine in PCOS. The biochemical improvements previously observed
with this treatment were not confirmed.
6.6.1 Comparison with other studies
The studies of Jaquet et al(1980) and Spruce et al (1984)
suggested encouraging therapeutic results from the use bromo¬
criptine in the treatment of PCOS. This was associated with an
improvement in the biochemical parameters.
Hirsutism was assessed in the trial of Spruce et al who used
subjective methods to evaluate the changes in hair growth.
Although improvement was reported by 50% of the patients, this was
only 'marked' in two (10%). The difference between the results of
the two trials was therefore not great. The failure to
objectively confirm changes in hair growth may have been due to
the methods used.
Hirsutism can be assessed relative to three parameters of
hair growth; the rate of hair growth, the number of growing hairs
and the thickness and colour of individual hairs. Photographic
techniques as described in this study measured the first two
parameters only. The thickness of hair can be measured by cutting
them and using a eyepiece micrometer as described by Ebling et al
1977). Attempts to apply this method proved unsuccessful because
there was a great variation in thickness of individual hairs
within one subject (Figure 3.2). It was not feasible to measure
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all the hairs present nor was it possible to randomly select hairs
for evaluation. There is no method available for assessing hair
colour changes.
In the trial reported here, menstrual frequency increased in
both groups of patients suggesting that this may have been a
placebo effect, although the precise mechanism by which this could
have occurred is unknown. A placebo response may therefore be the
reason for the significant improvement in menstrual frequency
noted in the earlier studies.
All patients who had an increased frequency of menstruation
were pleased, emphasising the pyschological benefit of regular
menstruation to many women. In such patients the use of
clomiphene to induce regular ovulation or oestrogen/progesterone
preparations to induce regular menstruation may be preferable
especially since some of the latter have been shown to cause a
slight improvement in hirsutism (Dewis et al 1985).
The fall in LH concentrations and LH:FSH ratio, and
reduction of the gonadotroph sensitivity to IKRH noted by Spruce
et al may be explained by the improvement in menstrual frequency
that was recorded (12 of the 2 0 patients had a regular menstrual
cycle whilst on treatment). A similar improvement in gonado-
trophin secretion was reported by Jaquet et al in the 13 of their
20 patients who had a restoration of regular menstruation. As
discussed earlier, a decrease in LH concentration and reduction of
LH:FSH ratio has been observed to follow an ovulatory cycle (Baird
et al 1977). Although ovarian function was not determined by
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Spruce etal, Jaquet et al had presumptive evidence of ovulation
from biphasic basal body temperature charts. Thus gonadotrophin
changes previously attributed to bromocriptine therapy may be a
direct result of restoration of ovulation. Likewise the improve¬
ments in androstenedione and testosterone (Jaquet et al) and in
testosterone (Spruce et al) which were not confirmed in the
present study, may also be a result of the increased frequency of
ovulation.
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6.6.2 Trial design problems
Bromocriptine is a drug with specific well recognised side
effects. Since an inert placebo was used, the comparison of
therapeutic responses could therefore be challenged. It was not
considered ethical to administer a placebo with similar side
effects. However, in practice not all patients on therapy
experienced side effects and one patient taking placebo withdrew
because of the typical symptoms of nausea and dizziness usually
associated with bromocriptine.
An error was made in choosing the sample size for this study
as no allowance was made for defaulters from therapy. The
preliminary trial (Spruce et al 1984) reported results having
excluded defaulters and therefore overestimated the responders.
Only 13 of their original 20 patients completed 12 months therapy
(a 35% default rate). Taking this into account, the sample size
for a controlled trial should have been larger. Because of this,
the study reported here has insufficient numbers to provide
conclusive results. Despite this it is relevant to note that the
two patients who reported improvement on therapy were still
markedly hirsute. Therefore, it is unlikely that a major
therapeutic role for bromocriptine exists.
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6.6.3 Problems of pulse analysis
Figure 6.3 shows two sets of LH data analysed by the methods
of Baird et al (1977) and Santen and Bardin (1973). The
importance of the method of analysis is clearly illustrated.
Three pulses are detected by the former analysis and 14 by the




EXAMPLES OF LH SERIAL DATA
(15 minute sampling interval)
Subject 28; 12 month study
*
Hours
j Pulse defined by Baird et al 1977
* Pulse defined by Santen and Bardin 1973
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The failure of time series analysis to detect regular pulses
may have been due to the long sampling interval used. In order to
evaluate this, LH data from control studies on 11 normal women
were analysed. This work is partly described in Murdoch et al
(1985). The protocol was similar to that described earlier as
applied to the patients with PCOS except that the sampling
interval was decreased to 5 minutes (6 subjects) or 10 minutes (5
subjects). The LH data obtained are given in Table 8.8. The
results gave clear confirmation of the existence of regular
harmonic patterns of LH secretion. The null hypothesis ('white
noise') was emphatically rejected for all 11 subjects using the
cumulative periodogram test (p<0.001). Three patterns emerged:
(1) LOW FREQUENCY VARIATION
Strong peaks at the lowest frequency (6h) were seen in 6 of
the 11 subjects (e.g. Figure 6.4 and 6.5). These were
indicative of a slowly varying change in LH concentrations
during the period of observation.
(2) HIGHER FREQUENCY VARIATION
Clear periodiogram peaks were seen in 10 of the 11 subjects
(e.g. Figure 6.4 and 6.5). The cycle lengths which
correspond with these peaks are given in Table 6.5.
(3) RAPID OSCILLATIONS
One subject exhibited a strong peak corresponding to a cycle
length of 72 minutes and in addition showed equally strong
peaks at two higher frequencies corresponding to cycles of 20
and 13.1 minutes (e.g. Figure 6.5). Peaks at the same
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frequency were also seen in eight other subjects although they
were less strong (e.g. Figure 6.4).
Spectral analysis therefore revealed that there were harmonic
variations superimposed on other harmonics and determination
of the frequency of each harmonic was possible. Such
oscillations have been observed by others (Veldhuis et al
1984, Filicori et al 1984), although statistical inter¬
pretations were not made. Their significance is unknown.
Sub-sampling of the 5 minute data produced 2 series of 10
minute data and 3 series of 15 minute data for analysis.
Considering the dominant harmonic alone, inconsistent results
were obtained with the 15 minute sampling interval but
consistent results were observed between the two 10 minute
series and between the 3x5 minute series. Accordingly, the
failure of spectral analysis to detect harmonic variations in
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Actual data Smoothed values obtained
from (1,2,3,2,1) weighted
moving average







As a preliminary to further investigations, eight patients
with PCOS were studied using 5 and 10 minute sampling intervals in
order to determine the dominant harmonics. The results are given
in Table 8.9 and the frequency and amplitude of the dominant
periodogram ordinates are given in Table 6.5. Compared with the
control group, there was an increase in frequency of the dominant
harmonics. The absolute pulse amplitude was also increased and it
therefore seemed likely that the elevated mean LH concenrations in
PCOS are due to a combination of changes in pulse frequency and
amplitude. As described previously, the latter may be a
consequence of the hyperoestrogenic state in PCOS which directly
sensitises the pituitary to LHRH. However, the increased pulse
frequency offers further evidence for an aberration of hypo¬
thalamic function in PCOS.
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TABLE 6.5
SPECTRAL ANALYSIS OF SERIAL LH DATA OBTAINED FROM
11 NORMAL WOMEN AND 8 PATIENTS WITH PCOS































5 minute sampling interval
Subject 1 21.5 34 3.6
2 30.3 72 25.4
3 26.4 40 5.5
4 23.4 100 9.6
5 9.5 60 3.2
10 minute sampling interval
Subject 6 16.1 60 4.8
7 13.4 55 3.2
8 10.1 120 4.2
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CHAPTER 7: GENERAL DISCUSSION
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7.1 SUMMARY OF CONCLUSIONS
The aim of this study has been to seek further evidence of a
deficiency of DA in the hypothalamus in PCOS which could be part
of the basic pathology of this condition. Such a deficency would
be expected to alter prolactin secretion since this is under tonic
inhibition from hypothalamic DA. The detailed studies of
spontaneous prolactin secretion and tests of lactotroph reserve
have failed to find a specific abnormality associated with PCOS.
Furthermore, the observation that preceding ovarian function
altered lactotroph responses may be the explanation for some of
the previous studies which suggested that abnormal prolactin
secretion was a feature of PCOS.
Dopamine agonist therapy given on a long term basis may be
expected to relieve the symptoms of PCOS should such a deficency
exist. Previous success with bromocriptine therapy in treating
the symptoms of hirsutism in PCOS prompted a controlled trial to
evaluate this treatment. No therapeutic value was found and no
consistent biochemical improvements were observed. An increase in
menstrual frequency occurred in both groups suggesting that this
was a placebo effect.
Anticipating that the DA deficency was the origin of the
typically elevated LH concentrations in PCOS, the latter was
studied in detail before and during therapy with bromocriptine.
No change was found in mean LH concentrations or in the amplitude
and frequency of the LH pulses. The observation was consistent
with the lack of clinical improvement found in this study.
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In conclusion, these studies have failed to provide evidence
which would support the hypothesis of a deficency of hypothalamic
DA as a cause of PCOS.
124
7.2 FURTHER STUDIES INDICATED
A clue to the origins of PCOS lies in the observation that
the syndrome starts at puberty. Although no longitudinal studies
have been reported, it is the general experience which is
confirmed by the histories of the patients studied here, that the
events occurring around puberty are crucial. In childhood the
hypothalamic-pituitary axis is highly sensitive to the feedback
effects of oestrogen. At puberty, there is a rise in gonado-
trophin secretion, largely due to a nocturnal increase in pulse
amplitude and frequency (Boyar et al 1972). This reflects a
primary hypothalamic event since it has been observed in agonadal
subjects (Conte et al 1975). As the ovary responds and secretes
oestrogen, there is a decrease in sensitivity of the hypothalamic-
pituitary axis to feedback inhibition although the precise
mechanism by which this occurs is unknown (Johnson and Everitt
1980). The balance between the ovary and the hypothalamic-
pituitary axis appears to be "set" at this time. Thereafter it
seems that each individual may retain her own pattern of LH
pulsatile secretion from one cycle to the next (Murdoch et al
1986). It is possible that an abnormal threshold of feedback
regulation may originate at puberty resulting in PCOS. Once set,
this pattern is retained despite intermittent ovulation,
spontaneous or induced. In order to investigate this hypothesis,
much more information on the control of puberty is needed and
therafter a prospective study could evaluate the factors which
trigger abnormal feedback regulation in PCOS.
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A more precise knowledge of the hypothalamic-pituitary
defect in this condition may lead to an effective therapy. A
possible hypothalamic deficiency of DA has been explored in this
study but was not proven. However, evidence has been obtained
which agrees with the concept that there is a hypothalamic problem
in these patients. The LH pulse generator is at the hypothalamic
level and this study has found that pulse frequency may be
increased. This may be a primary problem or may result from
altered feedback control.
Abnormal ovarian function in PCOS results in alteration of
the usual feedback effects on the hypothalamus. Progesterone is
the single unequivocal factor that has been found to change LH
pulse frequency. In the normal cycle, pulses in the luteal (pro¬
gesterone dominant) phase are slowed down to every 4 to 6 hours
(Santen and Bardin 1973). Amenorrhoeic and oligomenorrhoeic women
do not experience cyclical inhibition by progesterone and it is
possible that under such circumstances the pulse generator
operates more rapidly than normal. Contradicting this hypothesis
is the lack of evidence to show that regular ovulation induction
and hence cyclic endogenous progesterone secretion corrects the
condition in the long-term.
The effect of oestrogens on LH pulses is less obvious. An
increase in frequency probably occurs during folliculogenesis
(Backstrom et al 1982) as oestradiol concentrations rise. In
patients with PCOS, oestradiol concentrations are within normal
limits although oestrone concentrations are elevated. The effect
of the latter on LH pulses is unknown but may be the cause of the
increase in frequency.
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Oestradiol and progesterone are not the only hormones
produced by the ovaries in response to stimulation. The ovarian
androgens, androstenedione and testosterone, may have an effect on
LH pulse frequency in women, although paradoxically testosterone
slows pulse frequency in male and female monkeys (Plant 1986) and
hence their importance is probably insignificant. Many other
ovarian factors are now being discovered e.g. inhibin, whose role
in the feedback regulation of LH is unknown. Any of these may be
altered in PCOS and may be the source of the problem.
An alternative explanation for the increased LH pulse
frequency is the possibility of an inherent abnormality of the
LHRH pulse generator. As was discussed in Section 1.1.2, DA is
not the only neurotransmitter which may be involved in LHRH
regulation. Any of these other factors may be altered. In
addition, the observation in monkeys of a close correlation
between the LH pulses and hypothalamic multiunit electrical
activity (Wilson et al 1984) suggests possible higher neuronal
regulating factors. These too may be implicated in the patho¬
physiology of PCOS and warrant further investigation.
Another area which deserves more consideration is the
possible existence of multiple pulses of LH. This suggests that
its secretory pattern is much more complicated than had been
previously appreciated. The physiological significance of these
pulses is uncertain. There are distinct actions of LHRH on the
gonadotroph, i.e. promotion of LH synthesis, storage and secretion
(see Chapter 1). These have been demonstrated to be related to
the dose and duration of LHRH stimulation. Therefore, every LHRH
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pulse may have a separate physiological function. Several hypo¬
thalamic sites have been shown to contain LHRH secreting neurons.
Possibly each secretes pulses of LHRH independently which would
then be reflected by multiple LH pulses. Considering the numerous
neurotransmitters found in the hypothalamus, separate regulating
factors may influence each individual pulse.
Further studies are therefore needed initially to confirm
the existence of these multiple pulses and thence to determine
their normal controlling factors. Subsequently, interpretation of
studies of the complex LH pulse patterns in patients with PCOS may
lead to a better understanding of the precise hypothalamic
pathology of this condition. The pathophysiology may then be
revealed and a cure found.
'0 never, never let us doubt
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TABLE 8.IB: PROLACTIN RESULTS OF MULTIPLE SAMPLING STUDY - CONTROL DATA (nrU/1)
Sarrples taken every 15 rrinutes for 6 hours frotT 08:30h
SUBJECT 1 2 3 4 5 6 7 8 9 10
371 217 214 201 212 548 476 257 118 355
390 190 177 151 186 439 311 227 <100 371
381 174 174 148 152 307 278 219 121 382
296 169 183 112 175 292 263 192 <100 399
335 170 194 149 164 218 256 193 <100 329
288 153 187 <100 151 210 223 192 <100 289
- 151 136 <100 132 - 184 171 <100 286
271 133 186 107 172 199 171 157 <100 234
239 <100 189 <100 179 182 181 195 <100 234
236 142 147 <100 180 174 <100 165 <100 229
229 158 192 143 139 181 170 141 <100 212
231 141 136 125 148 133 143 123 <100 246
188 159 149 103 153 182 150 176 <100 224
213 157 140 106 169 142 125 179 <100 -
175 149 162 213 <100 153 150 140 <100 221
171 139 143 267 147 183 193 140 <100 218
222 157 152 272 131 185 135 159 <100 355
202 168 - 233 120 140 166 155 <100 444
224 174 163 259 <100 172 166 173 <100 423
250 174 120 244 153 215 <100 183 <100 439
219 149 154 122 <100 213 185 191 <100 368
200 140 - 105 <100 182 202 <100 <100 360
215 - - 186 <100 160 174 135 <100 303
205 - 184 <100 148 201 138 109 302
MEAN 250 148 165 156 141 213 195 171 102 314
146
TABLE 8.2: OVERNIGHT PROLACTIN CONCENTRATIONS (rrU/1 )
(hourly blood sarrpling)
TIME (h) POLYCYSTIC OVARY SYNDROME PATIENTS
1900 288 322 279 340
209 136 344 150
135 190 320 203
153 275 318 190
2400 164 288 256 210
264 423 327 350
389 277 344 374
577 237 595 411
0400 752 292 524 620
943 402 735 732
826 508 617 515
1006 487 642 436
492 396 652 390
1000 310 200 280 197
CONTROLS
1900 235 255 100 850 325 325
125 340 100 440 265 175
185 275 230 310 295 240
190 380 245 485 330 320
175 250 250 660 240 400
2400 205 320 240 425 245 470
200 310 190 350 245 700
- 215 295 665 245 700
410 415 325 575 370 690
0400 335 420 285 440 480 685
535 320 385 635 500 685
575 - 475 595 525 600
410 415 625 - 425 475
425 535 295 - 365 350
175 305 175 400 305 255
1000 100 185 125 235 195 190
14 7
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TABLE 8.4: INDIVIDUAL RESULTS OF NUMBER OF HAIRS GROWING





of treatment of treatment
0 6 12 0 6 12
42 76 76 76 36 20 23
16 38 34 33 24 14 14
39 96 85 41 28 24 16
46 26 38 16 41 49 43
49 33 33 33 38 38 42
41 50 48 56 13 16 13
1 4 2 4 13 13 12
PLACEBO GROUP
33 74 59 67 25 25 29
28 2 26 25 61 57 71
36 30 30 30 36 26 34
23 21 18 20 32 28 29
37 21 8 28 45 - 28
52 37 26 41 26 30 30
57 7 1 2 27 30 33
48 6 8 1 5 7 7
58 30 16 17 14 16 22
150






of treatment of treatment
0 6 12 0 6 12
42 .36 .39 .34 .36 .34 .34
16 .39 .42 .36 .29 .36 .31
39 .31 .26 .21 .34 .39 .29
46 .21 .18 .21 .29 .18 .23
49 .21 .16 .10 .23 .29 .29
41 .42 .39 .23 .18 .39 .21
1 .21 .18 .18 .18 .21 .18
PLACEBO GROUP
33 .36 .36 .36 .29 .31 .39
28 .34 .31 .34 .36 .36 .31
36 .31 .26 .34 .21 .23 .31
23 .31 .29 .29 .39 .36 .26
37 .26 .23 .23 .34 - .26
52 .26 .31 .26 .29 .29 .31
57 .18 .21 .26 .29 .42 .44
48 .23 .39 .31 .34 .29 .23
58 .34 .23 .29 .26 .29 .29
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TABLE 8.6A: GONADOTROPH!N CONCENTRATIONS DURING TRIAL: MULTIPLE SAMPLING STUDY AND RESPONSE TO LHRH (100 ug IV]
- BROMOCRIPTINE GROUP
aajer 49 12 5 1 41 16
I M»H-6CFTTSW 0 6 12 0 6 12 0 6 12* 0 6 12 0 6 12 0 6 12 |
| i 124 6.1 142) 7.9 53 64 9.7 10/ 534 124 184 144 194 184 25.9 6.7 34 1.9 |
2 13.2 6.5 133 64 5.7 64 134 10.7 484 13/ 14.7 14.9 194 204 22.9 64 34 24 |
j 3 14.9 7.1 1223 54 54 54 14/ 154 404 124 144 13/ 30.9 19.1 23/ 5.5 14 24 j
4 13.5 6.7 13.1 44 44 44 15.1 144 554 12.1 10.9 124 254 17/ 214 44 14 14 j
5 164 5.9 124 54 44 54 154 114 32.1 11.1 144 114 16/ 234 224 64 24 1/ j
1 6 134 5.1 11.3 54 6.1 44 143 11.1 39.5 94 144 164 25.9 22.5 21.5 6.7 24 2.1 |
j 7 124 5X1 134 4.7 44 44 15/ 104 99/ 124 124 134 254 184 194 64 1/ 24 j
1 8 154 44 13.9 64 4.1 4.1 134 134 464 104 114 154 25.7 214 19/ 5.9 2.1 14 |
9 134 74 13.1 6.1 4.7 3.9 11.7 124 35/ 11/ 174 144 164 23.9 254 8.9 24 34 j
10 134 9.6 10.9 6.5 54 44 104 114 304 124 13.9 134 22.7 214 254 8.9 24 34 |
I 11 184 74 104 54 54 64 94 94 814 10.7 134 12.9 184 21.1 174 74 2.7 2.7 |
12 15.1 64 11.7 54 44 54 74 9/ 574 12.1 134 13.7 214 25/ 224 74 24 1.9 j
1 '3 154 6.1 144 74 54 44 74 12.1 364 114 16.5 13.9 254 25.1 254 64 1.7 2.9 |
W 134 54 144 5.7 54 44 7/ 16/ 24 104 154 134 164 214 254 54 4.1 24 |
1 '5 15J0 53 114 5.7 34 5.1 13.1 144 574 114 124 144 - 184 254 4.7 2.7 14 |
16 14.9 53 114 54 34 44 114 114 49.1 13.1 174 184 - 164 24 7.7 24 24 j
17 1325 114 134 64 44 4.1 10.9 10/ 123 10.7 164 214 - 154 254 7.1 - 24 j
18 154 7.1 114 64 54 44 94 84 44/ 14/ 134 20.9 - 254 34 7.9 - 3.1 j
I 19 14.7 6J0 114 44 44 64 84 154 704 124 15.7 16.9 - 253 194 5.7 27 1/ |
20 194 53 144 44 44 6/ 7.7 17.7 49.1 114 14.1 154 - 254 184 54 2 14 |
21 14.1 53 184 44 34 53 7.1 144 51.9 134 12.9 13/ 194 22.7 21/ 74 19 24 j
1 22 144 144 6.5 64 34 4.7 74 11.7 36/ 114 134 22.1 154 29.9 24 54 2 24 j
25 134 33 12.9 54 7.1 44 124 104 35.7 11.7 16.5 - 18/ 234 164 54 27 2.9 |
1 21 164 84 124 5.9 64 3.7 11.9 94 324 124 44 6.7 34 214 174 54 21 24 |
, Nten LH 144 7J0 124 5.7 4.9 5J0 11.1 124 484 11.9 14.5 154 204 21.9 22.1 6/ 2/ 24
1 lb. of pulses 3 4 4 4 3 2 3 4 4 0 5 3 3 4 3 4 3 3 |
I Nfen arplHirfe 34 23 5.1 14 24 24 44 5.7 21.9 - 3.7 3/ 4/ 64 44 24 14 14 |
1
| LHresCTSS | Cf 14.7 . 44 74 34 3.7 10.7 8.7 48.7 12.1 14/ 134 13.7 214 19.7 74 3.5 24 |
| "toORH j 20' 394 - 74 114 44 44 21/ 25/ >290 494 33.1 484 574 424 484 254 134 8.1 j
| 40' 604 - 7.7 134 44 64 - - >290 906 - 478 858 610 992 2D 144 - |
1 1 ®'
1 1
604 - 8.1 124 4.4 64 — 33/ >290 74/ 65.1 994 733 814 593 25.7 114 84 j
1 F9H u/l (nffin 4.9 323 34 3.1 2.7 3.5 4.7 34 44 34 34 4.1 3/ 34 3.9 44 3/ 3/ |
1 of 6 sarples)
! 1
| fW | 0' 625 44 34 34 3.7 44 44 44 64 34 4.1 3/ 34 3.9 44 3/ 3/ j
| respcrse To | 20' 82? - 74 54 44 44 7.1 6/ 8.9 84 54 84 54 5/ 54 84 54 4.7 |
| LPFH j 40' 9.3 - 7.7 74 44 64 - 54 94 7/ - 94 64 7/ 64 8.1 7.9 - |
j 60'
1 1
94 — 8.1 4.9 4.4 64 - 34 84 44 74 44 6.1 84 6.9 74 74 64 j
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35 2 33 37 48
I NCN1E6 CF T-ERTY 0 6 | 12 1 0 6 12 0 6 12 0 6 12 0 6 12 0 6 12
j 1 as ao | 12a | 4a 4.7 2.7 12a sa 11a 12a 15a 13a 7a 9a sa 5a 7.1 sa j
1 2 14.3 11.6 | lia j 5.1 4a 4a 11a 9a Da 12a 12a 12.5 sa 9a Da 5a 4.1 6a |
| 3 as 12a | 10a | sa 4a - 12.9 sa 9a wa 22a 13.9 7.1 6.9 sa 5a 4a 3a j
1 4 13j0 12^ | 10a | sa 3.1 - 11a 6a 11a 13a 17a 13a sa sa 7.9 4.9 3a 3aj
1 5 Da KL4 j sa | 5a 3a 4a 9a 5.7 12.1 10.9 wa 12.7 sa sa 6.9 4a 3a 3a |
! 6 11.1 13-4 | 13a | 4a 3a 4.1 sa 9a 11.9 12.7 13.1 13a 6.7 6a sa 4a 3.9 4a j
j 7 12.9 12a j 11a | 6.1 5.7 4a 10a »a 11.9 12a 16.1 12a 5.7 sa 8.1 5.1 4a 4a j
8 11.5 10.91 9.7 j 4a sa 4a 12a sa lia 11a 15.9 11.7 4a sa 13. 6a sa 4a j
i 9 10.7 12a | 13.7 j 4.7 5.1 4.1 11a 8.1 10.7 9a wa 13a 7.9 sa sa 4a 4.1 4.91
10 VU wa | 11.1 j sa 4.9 5a 13a sa lia 9.1 wa 12.7 7a 6a 9a 4a 4.1 4a j
: 11 a3 11a j 13.7 | 5a 4a 4.1 13.1 9a 11.9 12.9 18.1 12a 6a sa 8a 2.9 4.1 sa j
12 KL5 10.9 j wa | 6a 4a 4.1 ca 7a 11.1 12a wa 15.1 7a 4a 7a 5.7 sa 3.9 j
1 13 15j5 wa j 12a 1 sa sa 4.1 10a 9a Da 11a 13.9 wa 7.7 4a 9.9 5.7 4a 3a |
; 14 a2 10a j isa j 5.1 5.7 4a 11a Da 9a 13a 12a 13a sa 4a 9a - sa 4a j
1 I5 Wa isa j 10a | 6a 4a 6a 11.7 7a 9a 13a 14.9 wa 9a 9a 7a sa 10.7 3.91
1 16 15w6 14a | 11.9 j sa 4a 4a 12a sa 11a 11a 13a 13a 9a sa 13 sa 11a sa|
I 17 12.1 12a j 17a | sa 3a 3a 12.7 sa 11a 10a lia 12a sa 6a 6a 7.1 Da 3.71
I 18 11.9 19a | 13a | 4a 3a 4a 12.7 sa 10a 15a 15a 11a 6.7 sa 9.7 6a 7a 4a |
1 19 16J3 - | 12a | 5.1 6a 2S 12a 8.7 9.7 W.7 wa 13.1 7a 4.7 7a sa 7a 4.1 j
23 13a via j wa j 6a 5.1 4a 13a 7a 10a 11.7 13a 15a 9a 4a 9a 6a 6.9 4.71
1 2' 15.1 a91 wa j sa 4a 5a 11a 9a D.7 10a 13.7 12a 6a 4.7 7a sa 7a 4.11
1 22 14.3 11a | 12a j 5.5 4a sa 12a 9a sa 13a 19a 11a 4a 4a 6a 7a 7a 3a|
1 23 !3a 20a | 10a j 5.5 3.7 sa 11a 8.7 9a 12a 15.7 W.1 6.1 6a 9a sa sa 8.9 j
1 2T 1
1
11a wa 13a 6a sa sa sa sa 7a |
1 Nfeai LH 13a 13a 12a sa 4a 4a 11.7 sa 10a 12a 15.1 13a 7a 6a sa sa ea 4a |
1 Ntx. of pulss 4 2 3 | 3 3 2 4 5 3 5 5 4 4 4 3 5 3 4 1
1 Nten arplHute 3a 5,1 4a | ia 2.1 2a 1.7 ia 1a 3a 4a 2a 1a 3a 2a ia 2a ia |
i 1
| U-trespcr® | C 15A 13a 19a 5.7 4a 4a 12a 13 7a 8.9 wa 13a 6a 7.1 7.7 4.71 sa | 7a |
j "toLHTH j 23' 6ia 117a 57a 15.9 11a W.7 32a 31a 37.1 3sa 52a 40a isa 12a 16a 4a | 49a | 16a |
i 1 40' 9ia ioia 8Ba 19a 12a W.7 29a 32a - 49a 57a 33a 23a 12a «a 5a | 35.9 j - |
1 1 eo»
1 1





| F9H iVI (itbsi 4a 3.7 3.9 3a 3a 3a 3a 3a 4a 4a 4.1 3a 3a 4a 4a 4a 2a 4a
1 of 6 saiples)
! 1
| | 0' 4a 3.7 3.9 5.7 4a 3a sa 4a 4.7 4a 4a sa 4a 4.9 5.7 I 2a 4.71
| respoise 1o | 23' 6a 4a 6a 15.9 11a sa sa 6.7 sa 7.5 7.7 5.7 6a sa 7a - 1 sa 7.7 j
j LPFH j 40* 13, 8a sa 19a 12a 7a sa 7.9 - 6.7 sa 6.7 7.7 4.7 sa - | 9a - |
| S3'
I I
7.9 7a sa iea 11.1 6.7 6a sa 9.1 7.1 sa 6.7 6.9 6.9 9.1 1 sa 4.7 j
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TABLE 8.6C: GONADOTROPHIN CONCENTRATIONS DURING TRIAL: MJLTIPLE SAMPLING STUDY AMD
RESPONSE TO LHRH (100 ug IV) - PLACEBO GROUP (cont) (Defaulters = 1 study only)
SUBJECT 52 18
MONTHS OF THERAPY 0 6 12 0 6
43 7 51 50
1 12.1 10.1 8.5 10.9 9.7 8.0 8.4 9.4 10.8
2 13.7 8.7 9.4 8.3 11.0 6.7 7.3 9.6 8.7
3 11.3 7.0 6.9 9.2 11.0 6.4 9.6 8.0 6.0
4 10.9 8.6 6.1 8.8 11.0 6.9 9.2 13.1 5.5
5 9.2 9.3 5.9 8.2 11.6 6.6 7.5 10.2 5.1
6 8.0 8.0 8.4 10.8 9.8 6.2 7.5 8.8 7.1
7 9.6 7.8 8.3 9.0 9.1 5.9 9.5 7.6 6.9
8 13.0 6.7 6.2 8.3 9.4 5.6 9.6 11.5 6.2
9 12.9 6.4 6.1 8.9 11.1 5.8 8.7 12.7 6.8
10 9.8 5.7 5.3 7.3 13.0 5.7 10.2 8.7 5.2
11 11.2 5.6 6.8 7.7 9.0 5.8 10.8 7.6 6.6
12 11.0 4.6 6.2 9.4 9.2 5.2 9.6 14.3 7.7
13 9.9 9.2 6.1 10.2 11.7 5.2 7.5 10.2 5.7
14 9.6 8.3 6.0 10.2 10.2 6.0 8.4 10.3 6.1
15 8.9 6.8 6.0 9.0 10.8 6.0 7.5 10.8 5.8
16 8.9 5.9 5.8 8.5 12.6 6.3 11.4 10.1 5.9
17 9.6 5.8 5.8 12.1 11.4 7.3 9.7 9.6 6.0
18 8.2 7.5 4.6 10.6 10.8 7.1 13.2 13.2 5.6
19 4.6 6.6 6.4 10.3 10.3 6.6 12.4 10.4 5.4
20 7.8 6.6 6.3 7.5 11.5 5.8 9.9 8.0 5.3
21 7.8 6.0 6.3 11.0 11.8 5.6 12.3 9.4 6.1
22 7.1 5.7 5.7 10.8 10.1 5.2 11.6 12.3 6.3
23 6.5 6.2 6.6 9.0 9.5 4.1 9.0 10.9 5.9
24 5.9 5.4 - 11.5 14.4 5.4 7.8 10.0 5.1
Mean LH 9.5 7.1 6.5 9.3 10.8 6.1 9.5 10.3 6.3
No. of pul ses 1 2 3 4 4 2 5 5 2
Mean amplitude 4.2 3.8 1.6 2.3 2.41 0.9 2.3 4.4 1.4
LH response 0' 7.0 5.6 11.2 f 13.4 6.7 13.0 11.6 4.8
to LHRH 20' 19.9 15.8 - 23.6 29.9 100.4 45.2 32.6 22.1
40" 30.7 20.4 - 39.1 37.7 151.8 45.2 33.6 22.9
60' 46.2 24.7 - 31.0 40.3 116.8 38.4 34.7 21.7
FSH u/1 (rrean 5.3 5.8 4.7 4.0 4.5 2.7 4.7 4.4 4.0
of 6 sarrples)
FSH 0' 4.7 5.8 11.2 3.8 2.3 7.9 4.4 4.1
response to 20' 7.3 8.2 - 23.6 6.0 8.9 8.3 3.3 5.4
LHRH 40' 7.2 9.3 - 39.1 7.0 10.7 7.8 5.5 5.6
60' 6.1 6.4 - 31.0 7.4 11.2 6.4 6.8 5.7
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TABLE 8.7A: STEROID CONCENTRATIONS DURING TRIAL - BROMOCRIPTINE GROUP
Months Testosterone Androstenedione Oestrone Oestradiol SHBG
Subject of study (rrrol /I) (rrrol/l) (prrol/I) (prol/1) (ittoI/I )
0 5.0 19.4 392 198 18
49 6 3.1 7.1 260 126 21
12 4.3 10.5 504 428 33
0 4.4 15.6 300 104 33
42 6 2.6 9.0 170 76 36
12 2.4 9.4 167 104 27
0 3.4 16.6 382 120 28
39 6 3.9 11.5 338 129 42
12* 4.8 19.3 632 670 48
0 4.3 28.2 372 212 37
1 6 3.2 14.2 449 357 57
12 3.5 11.2 292 98 51
0 4.1 24.0 326 296 24
41 6 3.1 13.2 306 197 28
12 3.3 12.0 379 247 27
0 6.0 31.6 305 170 -
16 6 3.7 10.8 283 105 34
12 3.7 11.7 305 260 39
0 2.6 11.4 320 179 _
46 6 3.0 5.9 253 65 -
12 - "" "
*Study coincided with rrid-cycle surge.
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TABLE 8.7B: STEROID CONCENTRATIONS DURING TRIAL - PLACEBO GROUP
PLACEBO GROUP
Months Testosterone Androstenedione Oestrone Oestradiol SHBG
Subject of study (rrol/1) (nrrol/1 (prrol/1) (prrol/1) (rrrol/1)
0 4.2 16.4 327 160 22
28 6 - 15.3 - 188 38
12 3.8 11.7 285 160 40
0 3.3 8.9 510 117 25
33 6 2.4 21.5 400 81 27
12 2.6 8.9 270 113 28
0 3.7 13.8 507 _ 72
23 6 2.3 5.0 274 120 80
12 3.7 8.7 298 117 76
0 3.6 18.2 420 248 29
58 6 3.4 13.8 332 201 31
12 3.0 11.2 275 350 26
0 4.0 42.0 433 131 37
37 6 2.8 12.2 335 - 67
12 3.7 5.9 310 131 46
0 1.9 7.2 _ 82 104
48 6 2.3 4.9 110 52 98
12 2.0 3.5 195 90 88
0 2.5 13.5 426 127 _
52 6 3.4 7.7 390 197 16
12 - - 548 253 -
0 2.7 10.3 133 89 29
18 6 2.2 7.8 168 171 36
0 2.6 9.8 360 174 20
57 6 2.7 9.1 - 181 45
12 3.1 12.0 560 179 24
0 3.8 16.8 380 145 27
36 6 4.3 15.3 - 206 -
12 3.2 10.0 337 166 23
156
TABLE 8.8A: SERIAL LH DATA (u/1) FROM NORMAL WOMEN SAMPLING IN THE EARLY
FOLLICULAR PHASE OF THE MENSTRUAL CYCLE - SAMPLES 1-34
(5iTinute sarrpling interval subjects 1-6; 10 ninute sampling interval
subjects 7-11)
SUBJECT 1 2 3 4 5 6 7 8 9 10 11
1 9.6 7.9 4.7 5.4 5.1 5.8 6.9 2.2 2.8 7.0 4.1
2 9.0 7.8 4.8 4.6 5.4 6.0 6.7 2.2 2.4 6.4 3.4
3 8.1 7.3 5.8 5.9 5.2 5.6 6.5 2.3 2.2 6.4 3.8
4 7.6 7.8 5.9 7.3 5.5 5.5 7.8 2.0 2.0 6.0 3.6
5 7.7 5.9 4.5 6.4 4.5 5.1 7.4 1.6 1.8 5.4 2.7
6 7.1 5.2 4.2 6.3 4.2 5.2 5.7 1.4 1.8 5.1 3.0
7 6.9 6.8 4.5 8.2 5.1 4.6 5.6 1.8 1.9 4.8 2.4
8 7.0 6.4 3.8 5.7 3.7 4.4 5.4 2.2 3.6 4.8 2.4
9 8.3 6.8 4.2 6.5 4.4 4.6 5.3 2.9 3.7 5.9 2.4
10 9.2 6.9 4.7 5.8 3.5 3.9 4.8 2.6 3.6 5.4 2.0
11 8.8 7.0 4.2 6.1 4.4 3.5 4.5 2.4 - 4.7 4.2
12 8.7 7.4 4.8 7.0 4.4 3.5 4.2 2.1 2.7 5.0 6.7
13 9.3 5.8 3.9 5.5 3.1 3.3 4.1 3.0 2.3 4.9 5.4
14 8.2 5.9 3.8 4.7 2.9 2.8 3.9 2.5 2.1 4.7 6.2
15 8.4 5.3 3.4 4.9 3.1 2.8 5.8 2.7 1.9 4.4 5.6
16 8.2 5.1 4.1 4.5 3.0 3.5 8.8 2.2 1.9 6.5 4.7
17 7.7 5.5 5.0 4.6 3.2 2.4 7.5 2.4 1.8 5.9 3.4
18 7.0 5.1 4.7 4.2 3.4 2.6 7.0 2.7 1.9 5.2 3.2
19 7.0 5.5 5.1 4.9 3.7 3.3 6.9 3.1 2.8 5.2 3.4
20 7.3 4.8 5.8 4.0 2.4 3.3 6.1 2.5 3.0 6.0 3.8
21 9.3 4.5 4.4 4.2 2.8 2.7 5.1 2.4 3.5 6.0 7.4
22 9.1 4.8 4.4 6.6 2.8 2.4 5.0 2.3 3.3 5.8 6.9
23 9.9 5.8 5.2 7.9 3.8 2.5 5.2 2.4 2.9 5.1 3.6
24 9.4 7.1 3.5 7.4 1.8 2.4 4.8 1.9 2.9 5.9 -
25 9.0 6.8 4.5 7.0 2.7 2.2 4.7 3.3 2.4 5.9 5.2
26 9.4 6.2 4.5 6.4 2.5 2.5 4.3 3.8 2.3 5.5 4.4
27 7.8 6.1 5.0 6.5 4.1 2.8 6.1 3.7 2.1 5.2 4.0
28 8.1 7.2 5.2 7.1 5.6 2.0 7.2 3.5 1.8 4.9 3.7
29 8.1 5.1 4.1 5.6 4.7 1.8 6.2 3.1 1.8 5.1 3.4
30 8.1 5.2 4.1 6.1 3.9 2.9 5.7 2.7 1.9 6.9 -
31 8.5 5.2 5.0 6.8 4.3 1.8 5.4 4.1 1.5 7.8 2.9
32 8.9 4.8 3.6 5.4 3.6 1.8 5.7 4.0 1.5 7.1 2.6
33 8.7 5.2 4.0 5.6 3.8 1.9 5.0 3.4 1.4 6.3 4.5
34 10.1 4.9 4.9 5.1 4.2 2.2 4.6 3.2 1.4 6.2 3.8
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TABLE 8.8B: SERIAL LH DATA (u/1) FROM NORMAL WOMEN SAMPLING IN THE EARLY
FOLLICULAR PHASE OF THE MENSTRUAL CYCLE - SAMPLES 35-68
SUBJECT 1 2 3 4 5 6 7 8 9 10 11
35 9.5 5.5 5.5 5.2 3.7 1.8 5.4 3.7 2.8 6.9 3.8
36 9.2 7.5 6.7 5.7 4.2 2.2 5.8 3.6 3.8 - 4.8
37 8.7 5.8 4.5 4.9 2.9 2.9 6.0 4.1 5.9
38 8.3 7.0 4.6 6.5 3.2 2.0 5.8 2.0 7.3
39 8.3 5.6 5.8 7.2 3.1 1.8 5.4 4.6 6.4
40 8.1 5.9 4.6 6.5 3.0 2.7 4.8 4.1 6.3
41 9.7 5.9 4.6 7.1 3.4 3.9 4.7 4.1 6.0
42 10.3 5.6 4.5 6.8 2.8 2.8 4.1 3.2 7.4
43 9.5 5.6 4.6 6.3 3.2 2.7 4.4 2.9 7.3 5.9
44 9.5 7.2 5.2 7.1 2.9 2.4 4.3 2.7 6.8 5.3
45 10.0 6.2 3.9 5.8 2.4 2.4 3.0 6.1 6.5
46 8.4 6.4 4.6 5.4 2.6 2.9
47 8.9 6.5 5.1 5.3 3.4 2.6 4.8 9.2 5.9
49 9.0 5.5 4.0 2.1 5.0 9.4
51 8.9 5.5 4.1 3.4
52 8.2 6.3 4.9 2.9
53 9.1 4.4 3.2 2.8
54 8.6 4.2 3.4 2.8
55 8.6 4.3 3.0 3.3
56 9.6 3.9 3.1 2.3
57 10.1 4.3 3.0 2.3
58 10.2 4.0 3.3 2.9
59 9.2 4.5 3.2 2.3
60 8.9 5.2 4.0 2.1
61 9.4 5.4 2.7 2.2
62 8.4 6.6 2.8 2.5
63 10.6 7.6 2.7 1.7
64 10.8 6.2 2.8 1.5
65 10.9 6.2 3.1 2.6
66 10.6 5.7 2.8 1.5
67 9.6 5.8 3.0 2.1
68 8.9 6.2 3.3 2.5
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TABLE 8.9A: SERIAL LH DATA (u/1) FROM PATIENTS WITH PCOS SAMPLING IN EARLY
FOLLICULAR PMSE OF THE CYCLE WHERE APPROPRIATE - SAMPLES 1-36
(5 rrinute sampling interval subjects 1-5; 10 ninute sanpling interval
subject 6-8)
SUBJECT 1 2 3 4 5 6 7 8
1 22.7 26.4 23.0 23.4 11.6 13.2 15.6 9.9
2 20.7 26.2 26.5 22.1 11.5 18.0 13.5 8.1
3 21.9 26.4 28.7 19.5 11.0 16.8 15.1 7.4
4 25.0 26.9 29.4 20.9 10.3 14.9 11.8 11.5
5 23.3 26.6 27.9 17.2 11.8 13.9 13.6 10.1
6 25.8 26.9 34.9 17.7 11.7 15.2 14.0 8.2
7 18.6 27.3 24.7 20.7 11.4 14.3 13.2 11.8
8 19.2 29.9 23.2 22.0 10.9 14.4 11.6 10.2
9 18.8 23.9 28.1 22.9 10.3 21.5 11.3 8.4
10 18.1 22.0 27.1 22.5 9.5 20.5 14.4 7.5
11 19.0 22.8 26.7 21.4 9.2 16.9 13.8 11.7
12 23.0 27.3 24.8 21.0 8.9 16.3 12.6 9.5
13 18.8 25.2 26.4 21.8 8.1 14.0 10.5 8.4
14 20.0 33.0 25.3 24.3 9.1 12.9 10.5 11.7
15 18.3 24.4 28.8 25.6 10.3 18.7 9.6 13.3
16 20.9 26.3 30.0 24.4 12.3 16.8 8.9 9.9
17 21.4 22.0 - - 11.2 16.6 7.8 10.9
18 23.1 22.1 26.1 23.4 10.3 15.6 14.7 8.4
19 22.4 20.6 24.3 22.5 9.7 13.8 15.5 13.0
20 23.6 21.4 24.3 22.5 9.1 - 14.2 13.2
21 23.4 20.1 26.1 21.5 9.1 15.0 12.0 10.6
22 17.3 19.6 26.7 20.3 8.7 16.6 11.1 9.9
23 19.4 26.9 25.7 24.7 7.9 17.6 9.9 8.8
24 20.5 28.3 26.2 25.6 7.8 16.7 12.0 8.8
25 21.8 34.2 26.5 25.0 10.0 13.5 17.3 7.8
26 20.0 32.3 24.7 20.7 10.7 18.1 16.5 7.3
27 21.0 28.1 25.2 21.2 11*4 17.5 14.2 7.9
28 19.7 24.3 26.5 22.5 9.8 16.5 13.1 11.0
29 21.8 31.7 27.1 20.5 10.0 14.1 10.9 11.7
30 17.8 24.4 26.2 18.2 9.4 - 16.0 12.8
31 19.6 27.6 25.4 19.2 8.6 16.0 17.5 12.0
32 21.2 26.7 25.7 21.7 10.1 18.1 15.9 12.3
33 22.5 30.5 24.7 25.8 10.1 18.1 15.9 11.6
34 24.7 28.9 24.7 26.9 10.2 16.2 12.6 10.8
35 23.4 30.6 23.2 24.2 9.3 16.3 17.0 10.3
36 23.2 26.4 23.2 23.5 9.1 13.3 16.9 10.0
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TABLE 8.9B: SERIAL LH DATA (u/1) FROM PATIENTS WITH PCOS SAMPLING IN EARLY
FOLLICULAR PHASE OF THE CYCLE WHERE APPROPRIATE - SAMPLES 37-72
SUBJECT 1 2 3 4 5 6 7 8
37 19.1 26.4 28.2 23.5 16.1 10.0
38 20.5 26.4 28.2 25.2 9.0 12.1 9.9
39 25.4 24.6 27.9 28.0 8.5 11.1 9.2
40 20.4 28.6 26.6 27.2 9.5 12.3 8.3
41 22.3 38.5 24.9 - 9.9 15.2 11.7
42 21.6 28.9 24.9 - 10.2 15.5 11.8
43 - 32.2 26.0 - 9.0 13.0 11.5
44 23.0 31.5 29.0 - 7.6 8.8
45 19.8 39.0 29.4 - 8.8 12.2 10.7
46 22.4 28.4 31.0 - 7.8 8.8
47 23.6 31.5 29.0 - 7.6 8.0
48 21.0 26.5 26.2 - 8.5
49 24.2 21.2 24.5 25.4 9.8
50 24.0 25.4 25.4 - 10.4
51 22.8 23.3 26.7 23.2 9.7
52 24.5 48.3 27.5 21.6 9.6
53 20.9 44.7 28.3 20.8 9.1
54 22.8 57.8 27.7 21.2 8.2
55 22.1 62.5 28.0 25.5 8.3
56 61.6 27.8 27.7 8.1
57 46.3 26.9 32.5 7.5
58 35.2 25.1 28.9 7.0
59 29.1 24.4 31.8 8.7
60 30.5 23.5 27.2 9.7
61 31.6 25.7 10.5
62 23.9 24.8 9.8
63 22.8 26.6 9.1
64 21.9 26.5 9.0
65 26.3 25.6 8.2
66 40.8 25.0 8.5
67 40.9 23.5 7.6
68 48.1 21.8 6.7
69 40.7 25.4 7.1
70 26.6 28.2 9.9
71 33.5 28.3 10.5
72 30.6 27.8 10.0
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